Raf-1 kinase regulates intestinal epithelial cell survival in response to pro-inflammatory stimuli by Edelblum, Karen Leigh
RAF-1 KINASE REGULATES INTESTINAL EPITHELIAL CELL SURVIVAL IN
RESPONSE TO PRO-INFLAMMATORY STIMULI
By
Karen Leigh Edelblum
Dissertation
Submitted to the Faculty of the
Graduate School of Vanderbilt University
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
In
Cell and Developmental Biology
May, 2008
Nashville, Tennessee
Approved:
David M. Bader, Ph.D.
Anne K. Kenworthy, Ph.D.
Richard M. Peek Jr., M.D.
D. Brent Polk, M.D.
Susan R. Wente, Ph.D.
ii
To those that possess courage and strength in the face of great odds,
and succeed because of those challenges
iii
ACKNOWLEDGEMENTS
This work was supported by a NIH CBMS (T32GM008554) training grant
and would not have been possible without the support of several people, from
both within and outside of the laboratory.  First I would like to thank my mentor,
D. Brent Polk, for providing me the opportunity to take a promising project and
run with it.  Brent has taught me not only the importance of looking at the big
picture, but also the significance of being able to succinctly relate science to
others.  He is a role model of the scientist I hope to become during my career:
well-rounded, intelligent, genuinely admired and respected among his peers.  Of
the greatest compliments that Brent has given me during my time the lab include
teaching me to become an independent thinker and entrusting me with the care
of his puppies.  Both experiences have taught me lessons in patience,
determination and how to approach a problem from multiple angles.  I would also
like to acknowledge the remaining members of my committee, Susan Wente,
Richard Peek, David Bader and Anne Kenworthy, for their encouragement and
advice throughout the course of my project.  I am also grateful to M. Kay
Washington, Tatsuki Koyama, and Taki Daikoku for their contributions to this
work, as well as Manuela Baccarini and Sylvie Robine for providing Raf flx and
villin-Cre mice.
As a member of Brent’s lab, I have been fortunate to work with talented
scientists that have become great friends.  I would like to acknowledge Fang Yan
for making the initial observations involving linking TNFR1 to cell survival, and
iv
Jeremy Goettel for his work in the generation of the TNFR1 addback cell lines
and his contributions toward that manuscript.  I am exceedingly grateful to Mark
Frey for answering endless questions, editing manuscripts when he already had
too much on his plate, and gladly making Friday chicken runs to Otter’s.  I also
have to thank Philip Dubé, Valerie Hilliard and Matthew Mullane for making the
lab a fun place to work everyday and their support over the last several months.
On a more personal note I would like to thank my parents, Glenna
Hornsby and Lawrence Edelblum, as well as Bill Hornsby and Anne-Claire
France for their love and support over the years.  Without them I would have
never made it to graduate school from the intensive care unit nearly six years
ago.  They have truly taught me what it means to persevere through difficult
times and how to inspire others to do the same.  I also have to thank my best
friends, Sandra Echegaray and Justus Kam, for traveling the road of higher
education with me and being supportive throughout the journey.
Lastly, I would like to acknowledge Blake Weinberger for his
support and encouragement.  He enthusiastically supports the time and energy I
have devoted to research, and understands me in ways that no one else can.  I
will always be grateful to have met someone that is a loyal friend, dance partner,
and inspiration, all in one.
vTABLE OF CONTENTS
           Page
DEDICATION........................................................................................................ ii
ACKNOWLEDGEMENTS .....................................................................................iii
LIST OF TABLES................................................................................................viii
LIST OF FIGURES .............................................................................................. ix
LIST OF ABBREVIATIONS .................................................................................xii
Chapter
I. INTRODUCTION........................................................................................1
Raf family of kinases ..................................................................................2
Raf isoforms and knockout mice......................................................2
Structure and function of Raf...........................................................3
Raf-mediated signaling pathways....................................................7
Activation of MAPK...............................................................8
Raf in cell survival...............................................................10
Cell signaling involved in apoptosis..........................................................11
Intrinsic apoptosis..........................................................................12
Extrinsic apoptosis – TNF receptor family .....................................16
NF-kB signaling .............................................................................17
The intestinal epithelium...........................................................................20
Intestinal architecture ....................................................................20
Inflammatory bowel disease ..........................................................22
TNF and NF-kB signaling in IBD ...................................................24
DSS colitis model ..........................................................................26
YAMC cell model ...........................................................................27
Objectives ................................................................................................27
II. MATERIALS AND METHODS .................................................................31
Mice and genotype confirmation ..............................................................31
Transgenic mice and genotyping...................................................31
Tamoxifen injections......................................................................31
Mucosal isolation...........................................................................33
Mouse treatment administration...............................................................33
DSS treatment...............................................................................33
TNF injections ...............................................................................34
vi
Histological assessment...........................................................................34
Organ culture ...........................................................................................35
Cell culture procedures and generation of cell lines.................................35
Cell culture procedures..................................................................35
Transient transfections ..................................................................36
Generation of TNFR1 addback colon epithelial cells.....................36
Generation of conditionally-immortalized Rafflx cells......................37
Cell lysate preparation..............................................................................38
Cell lysates, SDS-PAGE, Western blot analysis............................38
Subcellular fractionation ................................................................39
Activation assays .....................................................................................39
Ras activation assay......................................................................39
Raf kinase assay ...........................................................................40
Immunocytochemistry ..............................................................................40
Apoptosis assays...........................................................................40
NF-kB staining in vitro ...................................................................41
Immunohistochemistry .............................................................................42
Antibodies and staining protocol....................................................42
X-gal staining.................................................................................43
In situ hybridization ..................................................................................43
Statistical analyses...................................................................................43
III. RAF PROTECTS AGAINST ACUTE COLITIS BY PROMOTING MOUSE
COLON EPITHELIAL CELL SURVIVAL THROUGH NF-kB ....................45
Introduction ..............................................................................................45
Results .....................................................................................................47
Raf protects against DSS-induced crypt injury and inflammation..47
Raf expression confers intestinal epithelial cell survival during
DSS colitis ..........................................................................54
Raf promotes hyperproliferation during epithelial regeneration .....54
Raf protects from DSS-induced apoptosis through NF-kB
activation.............................................................................60
Discussion................................................................................................69
Acknowledgements ..................................................................................75
IV. TNFR1 PROMOTES TNF-MEDIATED MOUSE COLON EPITHELIAL
CELL SURVIVAL THROUGH RAF ACTIVATION OF NF-kB...................76
Introduction ..............................................................................................76
Results .................................................................................................... .79
TNFR1 is required for cell survival in the presence of TNF ...........79
TNF promotes MAPK activation in a Ras-independent manner ....84
TNFR-induced cell survival is Raf-dependent ...............................87
MEK activation is not required for cell survival downstream of
TNFR1 ................................................................................95
vii
Raf mediates cell survival through activation of NF-kB .................98
Discussion..............................................................................................101
Acknowledgements ................................................................................110
V. SUMMARY AND FUTURE DIRECTIONS..............................................111
Summary of findings ..............................................................................111
Raf in DSS-induced cytokine signaling ..................................................114
TNF and TNFR signaling in the colon epithelium...................................115
Raf involvement in NF-kB signaling .......................................................117
Raf in colon cancer development ...........................................................120
Concluding remarks ...............................................................................122
REFERENCES .................................................................................................123
viii
LIST OF TABLES
Table                                                                                                          Page
1.1 Immune cell function in IBD......................................................................23
2.1 Genotyping PCR primers .........................................................................32
ix
LIST OF FIGURES
Figure                                                                                                         Page
1.1 Schematic representation of Raf-1 functional domains and
phosphorylation sites.......................................................................4
1.2 Model of canonical MAPK signaling downstream of receptor tyrosine
kinase activation..............................................................................9
1.3 Intrinsic apoptotic pathways .....................................................................13
1.4 TNF receptors stimulate both pro- and anti-apoptotic signaling
pathways .......................................................................................16
1.5 NF-kB signaling pathway .........................................................................18
1.6 Colon epithelial crypt architecture under normal and inflamed
conditions ......................................................................................21
3.1 Inducible villin-Cre ERT2 expression induces LacZ recombination..........49
3.2 Raf expression is absent in inducible Raf intestinal epithelium-specific
knockout mice ...............................................................................50
3.3 Raf KOIE mice exhibit increased crypt injury and inflammation resulting
from acute colitis............................................................................51
3.4 Loss of Raf expression results in worsened clinical signs of colitis ..........53
3.5 Raf protects from apoptosis in response to damage in the intestinal
epithelium......................................................................................55
3.6 Raf is required for the epithelial hyperproliferative response following
DSS-induced injury........................................................................57
3.7 Raf expression does not effect the number of Lgr5-positive cells in the
colon epithelium.............................................................................58
3.8 Loss of Raf results in decreased ERK activation in the colon epithelium
during recovery..............................................................................59
3.9 Raf is required for intestinal epithelial cell survival in response to DSS
in vitro............................................................................................61
3.10 36-50kD DSS induces colon epithelial apoptosis in vitro..........................62
x3.11 Raf is required for DSS-induced ERK and NF-kB activation ....................64
3.12 MEK activation promotes DSS-induced apoptosis ...................................65
3.13 MEK inhibition does not block DSS-induced apoptosis in the absence
of Raf.............................................................................................66
3.14 Raf is required for NF-kB nuclear translocation in response to DSS
treatment .......................................................................................67
3.15 NF-kB activation rescues DSS-induced apoptosis in the absence of
Raf expression...............................................................................68
3.16 Raf promotes NF-kB activation in the colon epithelium in response to
DSS-induced injury........................................................................70
4.1 TNFR1 mediates colon epithelial cell survival signaling...........................81
4.2 TNFR1 is required for TNF-mediated cell survival in vitro ........................82
4.3 TNF-induced activation of TNFR1 promotes both pro- and anti-
apoptotic signaling pathways.........................................................83
4.4 TNF promotes MAPK activation in a Ras-independent manner...............85
4.5 TNF stimulates Raf kinase activity ...........................................................86
4.6 Cre expression is restricted to the intestinal epithelium ...........................88
4.7 Constitutive Cre expression induces LacZ recombination........................89
4.8 Raf expression is absent in constitutive conditional Raf knockout mice...90
4.9 Raf protects against TNF-stimulated colon epithelial cell apoptosis.........91
4.10 Raf promotes cell survival in response to TNF treatment in an organ
culture model.................................................................................93
4.11 Isolation and characterization of Rafflx colon and gastric epithelial cells ..94
4.12 Raf is required for colon epithelial cell survival in response to TNF .........96
4.13 Raf kinase inhibitor induces apoptosis in colon epithelial cells following
TNF exposure ..........................................................................................97
xi
4.14 Anti-apoptotic signaling downstream of TNF receptors is MEK-
independent .............................................................................................99
4.15 Loss of IkB expression results in constitutive NF-kB nuclear
translocation ................................................................................100
4.16 NF-kB activation rescues TNF-induced apoptosis in the absence of
Raf...............................................................................................102
4.17 Raf is required for TNF-stimulated NF-kB activation in vivo...................103
4.18 Raf is required for increased expression of cIAP1 in response to TNF
stimulation ...................................................................................104
4.19 TNFR1 regulation of both pro- and anti-apoptotic signaling in colon
epithelial cells ..............................................................................108
5.1      Raf promotes colon epithelial cell survival through NF-kB through
MEK-independent mechanisms...................................................113
5.2      Potential involvement of Raf in regulating NF-kB transcriptional co-
activators .....................................................................................119
xii
LIST OF ABBREVIATIONS
APC – antigen presenting cell
ASK1 – apoptosis signal-regulating kinase
CR – conserved region
CRD – cysteine-rich domain
DAPI – 4',6-diamidino-2-phenylindole
DD – death domain
DSS – dextran sulfate sodium
EGF – epidermal growth factor
EGFR – epidermal growth factor receptor
ERK – extracellular signal-regulated kinase
FADD – Fas-associated death domain
FBS – fetal bovine serum
H&E – hematoxylin and eosin
IAP – inhibitor of apoptosis protein
IBD – inflammatory bowel disease
IFN – interferon
IkB – inhibitor of kB
IKK – IkB kinase
IL – interleukin
i.p. – intraperiteoneal
ISOL – in situ oligo ligation
xiii
JNK – c-Jun N-terminal kinase
KO – knockout
KOIE – intestinal epithelium-specific knockout
KSR – kinase Suppressor of Ras
MAPK – mitogen-activated protein kinase
NF-kB – nuclear factor kB
NSD – neutral sphingomyelinase domain
PBS – phosphate buffered saline
RBD – Ras binding domain
RHD – Rel homology domain
RTK – receptor tyrosine kinase
S – serine
siRNA – small interfering RNA
T – threonine
TNF – tumor necrosis factor
TNFR – tumor necrosis factor receptor
TRADD – TNFR-associated death domain
TRAF – TNFR-associated factor
TUNEL – terminal UTP-nucleotide end labeling
Y – tyrosine
YAMC – young adult mouse colon
1 CHAPTER I
INTRODUCTION
A single layer of epithelial cells serves as the sole interface between the
organism and the contents of the gastrointestinal tract, underlining the
importance of regulating cellular viability in a luminal environment full of
pathogens, toxins and cytokines.  A balance between cellular proliferation and
apoptosis is necessary for maintenance of this critical barrier.  The molecular
mechanisms by which intestinal epithelial cells are able to survive in this
environment and how loss of normal regulatory processes may lead to
inflammatory bowel disease (IBD) are just beginning to be understood.  The
experiments described in this thesis will examine the molecular mechanism by
which Raf kinase mediates colon epithelial cell survival in response to injury and
inflammatory stimuli, including dextran sulfate sodium (DSS) colitis and tumor
necrosis factor (TNF), respectively.  First, the structure and function of Raf in cell
signaling pathways will be presented followed by a brief summary of cell
signaling involved in apoptosis downstream of TNF activation.  Lastly, the
contribution of these cell survival signaling pathways and colon epithelial
apoptosis to the pathogenesis of IBD will be reviewed.
2Raf family of kinases
In 1983, Ulf Rapp first identified oncogenic v-Raf (named for rapidly
growing fibrosarcoma), the gene responsible for murine sarcoma virus 3611-
mediated transformation (1).  The same year, another group identified v-mil, a
similar gene sequence capable of inducing transformation in the naturally
occurring avian retrovirus MH2 (2).  Soon afterwards the cellular homolog, c-Raf
or Raf-1, was mapped to mouse chromosome 6 (3), and human chromosomes 3
and 4 (4).  Together, these groups identified v-raf as the first oncoprotein with
serine/threonine kinase activity (5).
 Raf isoforms and knockout mice
Identification of the cellular counterparts to v-raf and v-mil resulted in the
discovery of the Raf family of kinases, consisting of three mammalian isoforms,
A-Raf, B-Raf, and Raf-1 (6).  Raf is a serine/threonine protein kinase that serves
as a key regulator of cell proliferation, differentiation, and survival.  Whereas Raf-
1 is ubiquitously expressed, A-Raf is most highly expressed in muscle and
urogenital tissues, and B-Raf is primarily located in the brain and nervous system
(7). Although the structure and function of the Raf kinases are highly conserved,
studies using knockout mice for each Raf isoform have demonstrated that Raf
family members are not functionally redundant in adult mice (8-11).  A-Raf
knockout (KO) mice are viable; however, at days 7-21 post partum these mice
display various neurological and enteric nervous system defects depending on
the genetic background (8).  B-Raf KO mice die at embryonic day 10.5-12.5 due
3to vascular hemorrhage induced by endothelial apoptosis (9).  Further studies
demonstrated that loss of B-Raf inhibits VEGF production resulting in decreased
angiogenesis in the placenta (12).  Raf-1 KO mice are also embryonic lethal due
to placental defects and increased hepatocellular apoptosis (13).  The generation
of B-Raf and Raf-1 double KO mice demonstrated that Raf expression is required
for embryonic development past the two-cell stage and that both isoforms are
functionally redundant for germ layer specification during the first half of
embryonic development (14).  Of the three isoforms, Raf-1 has been the most
extensively studied and characterized both in structure and in function.
Structure of Raf-1 kinase
Although the precise sequence of events governing Raf activation remains
unclear, protein binding and phosphorylation of multiple residues including S259,
S338, Y340/341, and S621 are required for Raf kinase activity.  The importance
of this complex regulation of Raf is demonstrated in oncogenic Raf variants,
which are constitutively active due to the lack of appropriate regulatory
mechanisms.
All Raf isoforms contain three conserved structural and functional
domains.  The amino terminal domains consist of conserved regions (CR) 1 and
2, which through intramolecular interactions inhibit the activity of the carboxy-
terminal kinase domain (CR3) (Figure 1.1)(6). The inhibition of the
Figure 1.1:  Schematic representation of Raf-1 functional domains and 
phosphorylation sites.  Raf is a serine/threonine kinase containing  three 
conserved regions.  CR1 contains a Ras-binding domain and a cysteine-rich 
domain, CR2 is a serine/threonine-rich region, and CR3 contains the kinase 
domain.  Serine (S), threonine (T), and tyrosine (Y) phospho-sites are indicated.
CRD
S338
Raf-1
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5Raf kinase domain by the N-terminal region prevents the phosphorylation of Raf
substrates in the absence of appropriate stimuli. Oncogenic variants of Raf
contain deletions of the N-terminal domain, resulting in constitutive activation of
the kinase domain and increased transforming capacity (15,16).
Interaction with the small GTPase Ras and changes in Raf
phosphorylation state relieve the conformational inhibition of the kinase domain.
The CR1 domain contains two distinct regions, a Ras binding domain (RBD) and
a cysteine-rich domain (CRD) (17,18).  The effector domain Ras possesses high
affinity for the RBD (amino acids 51-131), and deletion of this region abolishes
Ras/Raf interaction (19-23).  A second Ras binding domain on Raf, located within
the CRD domain of CR1 (amino acids 139-184), becomes unmasked once Ras
binds to the RBD.  This shift relieves the autoinhibition of the C-terminal domain
allowing activating kinases to access and phosphorylate multiple residues
necessary for kinase activation (24).
In addition to serving as a secondary Ras binding site, the Raf CRD
contains a zinc finger domain, which possesses significant sequence homology
to the C1 domains of protein kinase C (PKC) and kinase suppressor of Ras
(KSR) (25,26).  This domain in Raf, KSR, and PKC has been implicated in
binding ceramide and other membrane lipids including phosphatidylserine
(27,28), which suggests that this protein-lipid interaction may be required for
kinase activation.
Another key regulatory domain is CR2, a serine-threonine rich domain
containing one of two serine residues recognized by the 14-3-3 family of proteins.
6Although Raf is constitutively associated with 14-3-3, phosphorylation of S259
induces a conformational change in the Raf/14-3-3 interaction, effectively
sequestering Raf in an inactive conformation in the cytoplasm (29).
Dephosphorylation of this serine enables kinase activation by relaxing the
autoinhibitory interaction between Raf N- and C-terminal domains.  Although the
mechanism by which S259 is dephosphorylated remains unknown, subunits of
protein phosphatase 2A (PP2A) have been identified in a complex with Raf
(30,31).
Several kinases phosphorylate Raf to promote kinase activation.  Yao et
al. (1995) reported that Raf-1 is a substrate of KSR through the use of an in gel
kinase assay in which activated KSR from ceramide- or sphingomyelinase-
treated HL-60 cells increased Raf activity toward its substrate MEK.  Tryptic
digestion and phosphopeptide analysis of KSR-stimulated Raf indicated that KSR
phosphorylates Raf on threonines 268 and 269.  Although KSR was unable to
activate a Raf T268/269V mutant in vitro, mutation of these sites to alanine
showed that T269 was the primary site of KSR phosphorylation (32),
demonstrating that T269 was a significant target residue for activation by KSR.
In addition to T269, several of the molecule’s activating phosphorylation
sites are located in the catalytic domain, CR3.  Phosphorylation of Y340/341 by
Src-family kinases is required for kinase activation, and mutation of these
residues to aspartate results in constitutive activation and increased transforming
capacity (33).  Phosphorylation of S338 by p21-activated kinase (PAK) kinases
(34) cooperates with Src phosphorylation of Y340/341 (33,35) to promote optimal
7activation of Raf kinase (36).  As a second 14-3-3 recognition site,
phosphorylation of S621 may prevent Raf dephosphorylation by protein
phosphatases (37).  S621 may be an essential autophosphorylation site since it
is phosphorylated in both resting and active states (29,38).  Mutation of this
residue to alanine completely abolishes Raf kinase activity (29).
In summary, activation of Raf kinase is dependent on multiple regulatory
events to ensure appropriate activation of downstream signaling pathways.
However, it is important to consider that the majority of the observations
concerning requirements for Raf activation were made in in vitro model systems
using overexpression of recombinant proteins.  Future studies analyzing
endogenous Raf kinase activation will provide further insight into the mechanism
by which Raf is activated in response to a broader variety of stimuli in specific
cell types.
Raf-mediated signaling pathways
Canonical Raf activation has been primarily characterized through
receptor tyrosine kinase activation of mitogen-activated protein kinase (MAPK).
However, recent literature indicates that Raf may play an important role in cell
survival signaling downstream of tumor necrosis factor (TNF) receptor (R) family
members, including Fas and TNFR1.  The requirement for Raf in cell signaling
and cellular functions will be discussed further in this section.
8Activation of MAPK
As an upstream component of the MAPK cascade (Figure 1.2), Raf
functions as a MAP kinase kinase kinase, which phosphorylates and activates a
dual-specificity MAP kinase kinase, MEK (MKK1).  MEK phosphorylates ERK
MAPK, which can then translocate to the nucleus to promote transcriptional
activation of several genes such as activator protein-1 (AP-1) and ELK-1 (39-42).
ERK also regulates cytoplasmic targets involved in cell migration including
paxillin (43) and components of microtubule assembly (44).
ERK activation plays an important role in cell proliferation through the
induction of nucleotide synthesis, chromatin phosphorylation, activation of
transcription factors, and promotion of cyclin D/CDK4 complex formation (45-47).
The diverse functions of MAPK signaling were first described in PC12
neuroendocrine cells [reviewed in (48)], in which nerve growth factor (NGF)
promotes sustained ERK activation resulting in differentiation, whereas transient
ERK stimulation by epidermal growth factor (EGF) induces cell proliferation (49).
In addition to being an integral component of the MAPK cascade, Raf has
been shown to function outside of the Ras/Raf/MAPK pathway.  Studies
 using a Raf construct that is unable to bind to MEK (T481A) demonstrated that
only a subset of cellular functions, including cell growth and transformation, are
impaired when Raf is uncoupled from MEK activation; however, Raf-mediated
nuclear factor (NF)-kB reporter activation and neurite differentiation are
unaffected (50).
RTK
Ras
GTP
Raf
KSR
MEK1/2
ERK1
ERK2
proliferation 
differentiation
P
P
PP
P
P
Figure 1.2:  Model of canonical MAPK signaling.  
Receptor tyrosine kinase (RTK) signaling promotes activation of Ras-GTPase, 
which recruits Raf to the plasma membrane through a high affinity binding 
interaction in the N-terminus of Raf.   Subsequent phosphorylation of Raf by 
kinase suppressor of Ras (KSR) and other kinases, promotes its kinase activity 
toward MEK, and MEK then phosphorylates ERK MAPK, which can activate 
cytoplasmic targets or translocate to the nucleus to promote transcription of AP-1 
or ELK.  In this model, KSR functions as both a kinase to phosphorylate Raf and 
a scaffold to bring Raf, MEK and ERK in close proximity to one another.
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Raf in cell survival
Following the initial identification of v-raf, the discovery that the Raf
oncogene could cooperate with Myc to promote tumorigenesis was one of the
first indications of Raf involvement in cell survival (51).   Whereas oncogenic Myc
promotes cell death, expression of an activated Raf (gag-v-Raf) postpones cell
death following growth factor removal in an interleukin (IL)-3-dependent
promyeloid 32D cell line (52).
Similar observations were made in Raf-1 knockout mice which are
embryonic lethal due to increased hepatocellular apoptosis (11).  Further studies
investigating the mechanism by which Raf regulates cell survival demonstrated
that Raf plays an essential role in inhibiting Fas-induced apoptosis by regulating
Fas expression and internalization (53,54).  In fibroblasts, Raf antagonizes
activation of the pro-apoptotic kinase, MST2, (55) indicating that the mechanism
by which Raf blocks Fas-induced apoptosis varies with cell type.
Due to the embryonic lethality of Raf KO mice, conditional knockout mice
have been generated to better address the role of Raf in specific cell types.
Using Cre/loxP technology, Raf has been shown to be anti-apoptotic in
cardiomyocytes through the regulation of apoptosis signal-regulating kinase 1
(ASK1), an upstream activator of c-Jun N-terminal kinase (JNK) and p38 MAPK
(56).  In macrophage-specific Raf knockout mice, Raf was shown to protect
macrophages from Salmonella-induced apoptosis through inhibition of caspase-1
(57).  In vitro studies have demonstrated that Raf-1 blocks intrinsic apoptotic
pathways through binding Bcl-2 at the mitochondrial membrane and directly
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phosphorylating Bad to release Bcl-2 from inhibition (58-60).  Interestingly, these
studies demonstrated a novel mechanism through which Raf promotes cell
survival independent of MEK/ERK activation.
In regard to the colon epithelium, KSR, an upstream activator of Raf, is a
key regulator of cell survival in response to TNF both in vivo and in vitro.  KSR
knockout mice and colon epithelial cells expressing a dominant-negative kinase-
inactive KSR or a KSR antisense construct show increased sensitivity to TNF-
induced apoptosis.  Furthermore, disruption of KSR kinase activity inhibits TNFR
activation of ERK MAPK and NF-kB, while pro-apoptotic signaling through p38
and JNK pathways is not impaired.  Since Raf has been reported to be a
downstream effector of KSR kinase activity, these findings suggest that KSR
activation of Raf may promote anti-apoptotic signaling in response to TNF
stimulation (61,62).
Taken together, these studies illustrate the cell type-dependent manner in
which Raf promotes cell survival in response to various stimuli.  Both cell culture
models and tissue-specific Raf knockout mice have shown that Raf can inhibit
apoptosis in several tissue types.  In addition, Raf activation of different cell
survival signaling pathways is independent of MEK activation.
Cell signaling involved in apoptosis
Cell death occurs through several processes including: necrosis,
apoptosis, anoikis and autophagy.  During necrosis, the cytoplasmic and nuclear
content of cells is released into the intercellular space resulting in inflammation
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[reviewed in (63)].  However, in 1972, Kerr et al. demonstrated that cells undergo
an evolutionarily conserved, programmed cell death.  This genetically controlled
form of cell death was termed apoptosis, based on the Greek word for “a falling
off” (64).  In multicellular organisms, apoptosis functions to remove senescent,
damaged or redundant cells by breaking down cell components into apoptotic
bodies, which are phagocytosed by macrophages (65).  Apoptosis occurring after
loss of anchorage to the extracellular matrix is termed anoikis (66).  Autophagy, a
process by which cells sequester organelles and cytoplasmic contents for
delivery to lysosomes, can either promote or protect from cell death depending
on the stimulus (67).  Further investigation is required to determine under what
conditions extensive autophagy results in cell killing, or whether autophagy
contributes to known cell death processes such as apoptosis and necrosis.  This
section will focus on the initiation of apoptosis in response to a variety of cellular
cues, through the activation of intrinsic pathways from intracellular signals or by
an extrinsic pathway responsive to extracellular events.
 Intrinsic apoptosis
Intrinsic apoptosis occurs following DNA damage or toxic stress, in which
mitochondria release cytochrome c from their intramembrane space (Figure 1.3).
Mitochondrial membrane permeability is controlled by both pro- and anti-
apoptotic members of the Bcl-2 family of proteins, all of which contain at least
one conserved Bcl-2 homology domain (BH) [reviewed in (68)]. Bax and Bad
Figure 1.3:  Intrinsic apoptotic pathways
Intracellular signals, such as DNA damage or genotoxic stress, induce apoptosis
through activation of pro-apoptotic Bcl-2 family members which promote
cytochrome c release from the mitochondria.  Cytochrome c binds to and 
activates Apaf-1, which stimulates caspase activation.  Caspases cleave various 
cellular substrates including endonucleases, such as poly ADP-ribose 
polymerase (PARP), leading to DNA fragmentation. 
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oligomerize with additional pro-apoptotic BH-3 motif-containing proteins to
promote cytochrome c release. Located at the outer mitochondrial membrane,
Bcl-2 and Bcl-Xl can bind to these BH-3 containing proteins to inhibit pore
formation and cytochrome c release, thereby inhibiting apoptosis.  Once
cytochrome c is released, it binds to apoptotic protease-activating factor (Apaf-1)
promoting activation of cysteine proteases (caspases), which target several
proteins essential for cellular function (69,70).  Inhibitors of apoptosis proteins
(IAPs), can prevent apoptosis via selective inhibition of specific caspases,
allowing these proteins to block both intrinsic and extrinsic apoptotic pathways
(71).
Extrinsic apoptosis – TNF receptor family
Extrinsic apoptotic signaling occurs following activation of death receptors
belonging to the tumor necrosis factor receptor family.  TNF was first described in
1975 as a potent, pro-inflammatory cytokine expressed by several cell types,
such as macrophages, T-cells, B-cells, and natural killer T-cells (NKT) (72).  The
TNF family of ligands include lymphotoxin-a (LT-a), Fas ligand, receptor activator
of nuclear factor kappa B ligand (RANKL), CD40L and TNF-related apoptosis-
inducing ligand (TRAIL), all of which are homotrimeric and share some sequence
homology primarily within residues responsible for trimerization (73).  TNFR1,
TNFR2 and Fas are among several receptors for TNF family ligands (74).  Both
TNFR1 and Fas contain death domains within the cytoplasmic portion of the
receptor, whereas TNFR2 does not (75).  Recruitment of several adaptor
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proteins, including TNF receptor-associated death domain (TRADD), Fas-
associated death domain (FADD), TNFR associated factor-2 (TRAF2) and
receptor interactive protein (RIP) (76-79) to the death domain of TNFR1 activates
pro-apoptotic signaling pathways (Figure 1.4).   Each adaptor protein promotes
apoptosis through different pathways: RIP induces NF-kB activation, FADD
stimulates caspase-8 and 3 activation (80), and TRAF2 activates several MAPK
pathways (81).
In addition to inducing apoptotic signaling, TNFR1 can also promote cell
survival pathways.  While TRAF2 stimulates p38 and SAPK/JNK to promote
apoptosis, TRAF2-mediated ERK activation is anti-apoptotic in response to TNF
in several cell types (81).  Similarly, RIP-induced NF-kB activation stimulates cell
survival or apoptosis in a cell-context dependent manner (82).  The role of NF-kB
in cell survival will be further addressed in the next section.  In summary, TNFR1
can stimulate both pro- and anti-apoptotic signaling pathways dependent upon
the cell type.
While the role of TNFR1 and its associated adaptor proteins in apoptotic
signaling is well-established, the role of TNFR2 in cell death remains unclear.
Although there is no death domain in TNFR2, the cytoplasmic tail of the receptor
contains a TRAF-interacting domain, which recruits TRAF2 and cIAP to the
receptor resulting in NF-kB activation (83).  However, overexpression of TRIP
(TRAF-interacting protein) prevents TRAF2-mediated NF-kB activation leading to
apoptosis (84).  A recent report suggests that TNFR2 may induce apoptosis in
Figure 1.4:  TNF receptors stimulate both pro- and anti-apoptotic signaling 
pathways.  TNFR1 promotes apoptotic signaling through recruitment of adaptor
proteins to the death domain (DD).  RIP, TRAF2, and FADD stimulate 
downstream signaling pathways to induce cell death.  However, activation of ERK 
and NF-κB is anti-apoptotic in some cell types.  Since TNFR2 lacks a death 
domain, the role of TNFR2 in apoptosis remains unclear.   TNFR2 is thought to 
induce cell death through binding of membrane-bound TNF or through a TRAF2-
interacting domain in the cytoplasmic tail.   TRAF-interacting protein (TRIP) has 
been shown to promote apoptosis by inhibiting TRAF2/cIAP interactions in 
response to TNFR2 stimulation.
cIAP
TNFR1
caspase-8
p38
TRADD
TRAF2
FADDRIP
NSD
DD
ERK
TNFR2
JNK
FADD
NFκB
?
anti-apoptotic
pro-apoptotic
pro-apoptotic
TNF
TNF
TRAF2
NFκB
TRIP
anti-apoptotic
16
17
antigen-presenting cells after binding to membrane-bound TNF (85).  Other
groups have demonstrated a requirement for TNFR2 in T-cell apoptosis through
activation of FADD and downregulation of TRAF2 (86,87).  Therefore, these data
indicate that each TNF receptor can independently induce pro-apoptotic
signaling.
NF-kB signaling
NF-kB is a significant mediator of inflammatory responses and a regulator
of target genes involved in cell proliferation, apoptosis, and oncogenesis.  The
five NF-kB family members, p65/RelA, RelB, NF-kB1 (p50/p105), NF-kB2
(p52/p100), and c-Rel share a Rel homology domain (RHD) involved in
dimerization, DNA-binding, and association with IkB inhibitory proteins (88).  Of
these family members, the NF-kB p65/p50 heterodimer is the most prevalent.  In
resting cells, binding to IkB  in the cytoplasm masks the nuclear localization
signal of NF-kB dimers.  TNFR signaling promotes activation of two MAP kinase
kinase kinases, NF-kB-inducing kinase (NIK) and MEKK1, which in turn activate
the IkB kinases (IKKs) (Figure 1.5). The IKK complex contains two catalytic
IKKa/b subunits and a regulatory subunit, IKKg (NEMO) (89-91).  IKK
phosphorylates IkB on serines 32 and 36 leading to IkB poly-ubiquitination by the
E3 ubiquitin ligase complex (92-94).  Degradation of IkB by the 26S proteasome
releases NF-kB for translocation to the nucleus (95).
NF-kB regulates gene activation by binding to the promoter region of
genes encoding several cytokines, chemokines, adhesion molecules, and other
Figure 1.5:  NF-κB signaling pathway
TNFR1 activates MAPKKKs, NF-κB-inducing kinase (NIK) and MEKK, to 
phosphorylate IκB kinases (IKK).  The catalytic IKKα and β subunits 
phosphorylate IκB promoting its ubiquitination and proteasomal degradation.  
Degradation of IκB allows NF-κB to translocate to the nucleus, where it is 
subsequently phosphorylated and promotes transcription of genes involved in 
pro- and anti-apoptotic signaling.
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pro-survival proteins including IAPs.  The effect of NF-kB activation on apoptosis
is largely dependent on cell type.  In lymphocytes, NF-kB promotes cell death by
working in conjunction with AP-1 to induce FasL expression (96), while in the
intestinal epithelium NF-kB potently induces inflammatory responses and inhibits
cell death (97,98).
The importance of NF-kB activation in preventing apoptosis was
demonstrated in p65 KO mice (99).  Similar to the phenotype seen in Raf-1 KO
mice, p65 KO animals show increased apoptosis in the liver and were highly
sensitive to pro-inflammatory stimuli.  In most cells, TNF stimulation alone is
unable to induce cell death; however, TNF treatment is sufficient to induce
apoptosis in p65 KO fibroblasts (100).
In summary, the biological outcome of signaling through TNFR is highly
dependent upon cell type and context.  While TNFR signaling can promote
apoptosis in certain cell types, it remains unclear as to why some cell types are
more susceptible to TNF-induced apoptosis compared to others.  Furthermore,
little is understood as to how or why TNFR1 activates both pro- and anti-
apoptotic signaling in a single cell.  Similar questions arise in regard to NF-kB
activation, which promotes transcription of genes involved in both cell survival
and cell death.  These questions are important because both TNF and NF-kB are
critical mediators of intestinal epithelial cell survival and apoptosis, both in the
context of maintaining intestinal homeostasis and in response to inflammation.
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The intestinal epithelium
The gastrointestinal epithelium is a dynamic tissue characterized by a high
cellular turnover rate leading to renewal of the entire intestinal epithelium every 3
to 5 days (101). This unique system is maintained by a balance of intestinal
epithelial proliferation, differentiation and apoptosis.  This interplay is already
established early in vertebrate development as the endoderm is converted from a
stratified cell layer into a differentiated intestinal epithelial monolayer.
Intestinal architecture
The mature intestinal epithelium consists of rapidly proliferative, columnar
epithelial cells located in crypts, from which cells differentiate and move up the
crypt-villus axis. To maintain a constant number of cells and a consistent
epithelial architecture, apoptosis serves as a mechanism to counterbalance rapid
proliferation (Figure 1.6)(101).  Under normal conditions, colon epithelial cell
apoptosis occurs at the surface epithelium and is associated with cell shedding
into the intestinal lumen (102).  Beneath the epithelium is the lamina propria, a
layer of loose connective tissue containing blood vessels, fibroblasts, and
lymphoid tissues.  Immune cells within the lamina propria provide immune
surveillance and enable host defense mechanisms in response to foreign
antigens.  Together, the epithelium and the lamina propria serve as a barrier and
coordinated defense against bacteria and other toxins present in the intestinal
Figure 1.6:  Colon epithelial crypt architecture under normal and inflamed
conditions.  (A)  Cells migrate from the base of the crypt toward the surface
epithelium where cells undergo apoptosis and are shed into the lumen.  
(B) During inflammation-induced injury, epithelial apoptosis is increased, 
resulting in decreased barrier integrity.  This barrier defect allows migration of 
pathogens from the lumen into the lamina propria leading to recruitment of 
neutrophils and macrophages.  Pro-inflammatory cytokines produced from 
immune cells can further inhibit barrier function and induce cell death, leading to 
cyclical inflammation and epithelial damage.
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lumen.  Defects in epithelial integrity and dysregulation of host immune
responses lead to the development of gastrointestinal diseases.
Inflammatory bowel disease
The major forms of inflammatory bowel disease (IBD) are Crohn’s disease
and ulcerative colitis.  Ulcerative colitis is characterized by extensive, superficial
mucosal ulcerations extending proximally from the rectum.  Increased numbers
of neutrophils are present in the lamina propria and crypts.  In contrast, Crohn’s
disease primarily affects the ileum, although it may occur anywhere in the
gastrointestinal tract, and is characterized by an accumulation of macrophages
often resulting in transmural inflammation.
Although the cause of IBD remains unknown, three factors are known to
contribute to the pathogenesis of these chronic inflammatory diseases, including
defects in barrier function, dysregulation of adaptive and innate immunity, and
impaired microbe recognition (Figure 1.6).
When the epithelial barrier is compromised, the immune system promotes
inflammatory cytokine production and upregulation of host responses to the
enteric microbiota (103).  The current understanding of function and contribution
of each immune cell type in the pathogenesis of IBD is described in Table 1.1.
Innate immune cells such as neutrophils and macrophages depend on cytokines,
chemokines, and adhesion molecules for recruitment to the site of injury to
amplify the local immune response (104). This increased production of cytokines
and chemokines can result in loss of tight junction stability, leading to a further
Table 1.1:  Immune cell function in IBD
Type of immune cell Function Involvement in IBD ref
Neutrophils Phagocytose bacteria and produce
cytokines
Exhibit an extended lifespan due to defective
apoptosis; cause tissue damage through release
of non-specific inflammatory mediators
(105)
Macrophages 1. Regulate inflammatory responses
to bacteria and antigens
2. Scavenge dead cells and foreign
debris
Enhance abnormal inflammatory response to
luminal antigens
(106)
Dendritic cells Primary APC to prime naïve T-cells 1. Prime abnormal T-cell responses to flora
2. Maintain T-cell inflammatory responses by
remaining in contact with T-cells in inflamed
regions resulting in increased cytokine
production
(107)
CD4+ Regulate suppression of immune
responses during homeostasis and
upregulate inflammatory response
Produce sustained levels of pro-inflammatory
cytokines
(105)
Regulatory
T-cells
(Tregs)
1.  Maintain immune homeostasis in
gut and self-tolerance
2.  Suppress T-cell proliferation
Decreased levels in IBD; IL-10 and TGF-b
suppress pro-inflammatory cytokine production
(108)
T-cells
Natural
Killer T-
cells
(NKT)
1.  Cytolytic activity through
secretion of perforin and granzyme
2.  Produce Th2 cytokines directly or
through regulation of conventional T-
cells
1.  Cytolytic activity directed toward intestinal
epithelial cells resulting in injury
2.  Cytolytic activity toward dendritic cells to
decrease immune responses
3.  Increase Th2 cytokine production
(109)
B-cells Produce antibodies to bacterial and
non-bacterial antigens
Loss of tolerance to commensal bacteria (105)
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disruption of epithelial integrity.  While the innate immune system promotes a
rapid response to bacterial and luminal antigens, adaptive immunity is necessary
to establish a sustained inflammatory response to following continuous epithelial
damage.
Components of the adaptive immune system also play an important role in
chronic inflammation.  Dendritic cells are involved in both innate and adaptive
immunity, and are recognized as the dominant antigen-presenting cell in the
lamina propria.   Live imaging studies show that dendritic cells form networks
under the epithelium and extend long processes between crypts to sample the
intestinal flora (110).  In the absence of inflammation, dendritic cells constitutively
express IL-10, which suppresses TNF production (111).  Several mouse models
of colitis demonstrate a requirement for B-cell and regulatory T-cell function in
response to chronic inflammation [reviewed in (103)].  Therefore, cells involved in
innate and adaptive immunity are necessary to maintain intestinal homeostasis
and protect from bacterial infection when the epithelial barrier is compromised.
TNF and NF-kB signaling in IBD
TNF is a primary mediator of chronic inflammation in IBD.  Increased
levels of TNF are recovered from serum and stool of patients (112,113), and in
situ hybridization in colon sections showed increased TNF mRNA expression in
macrophages (114). Importantly, neutralizing monoclonal antibodies against TNF
reverse disease activity and induce remission in some IBD patients (115,116).
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Both innate and adaptive immune cells produce increased levels of pro-
inflammatory cytokines including TNF and interferon-g, which can promote
epithelial apoptosis (117).  Increased apoptosis is seen throughout the length of
the colonic crypt in IBD patients (118,119).  In a study by Marini et al., anti-TNF
antibody treatment reduces epithelial cell apoptosis and Fas/CD95 expression in
the intestinal epithelium of Samp1/Yit mice, which develop spontaneous ileitis
(120).  Furthermore, lamina propria mononuclear cell apoptosis is increased
resulting in decreased chronic inflammation in these mice.  These findings
demonstrate an important role for TNF signaling in the pathogenesis of IBD, by
regulating host immune responses, barrier function, and intestinal epithelial cell
survival.
Among known intracellular signaling pathways downstream of TNF, IKK
inhibition has been suggested as a therapeutic target for IBD (121). Elevated NF-
kB activation is commonly seen in inflamed colon mucosa of IBD patients (122),
prompting investigations into the role of NF-kB activation during intestinal
epithelial damage.  In fact, 5-aminosalylic acid (5-ASA), an effective therapy for
ulcerative colitis, inhibits IKK activity in intestinal epithelial cells (123,124).
Furthermore, use of an IKK inhibitor peptide, which blocks association of IKKb
and with IKKg/NEMO, reduced the severity of colitis and production of pro-
inflammatory cytokines (125).  However, complete deletion of IKKb in the
intestinal epithelium does not protect against colitis (126), indicating that NF-kB
could be a therapeutic target in one cell type but not in another, complicating the
utility of generalized NF-kB targeting in IBD.  However, the continued study of
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NF-kB is still a key to understand the mechanism and identify potential targets for
IBD treatment.
DSS colitis model
Several mouse models of colitis have been developed to better
understand the contribution of various signaling pathways in the pathogenesis of
IBD.  In one well-characterized model, dextran sulfate sodium (DSS) is
administered via drinking water to induce acute colitis (127).  Although the exact
mechanism by which DSS induces colitis remains unknown, studies show that it
directly induces crypt injury (128,129), pro-inflammatory cytokine production
(111,130), and decreases barrier function (131).  Secretion of both TNF and IL-6
are enhanced in response to DSS-induced injury, and are thought to be the
primary mediators of tissue damage in this model [reviewed in (132)].
During recovery from acute DSS colitis, epithelial hyperproliferation
occurs, presumably to restore barrier integrity.  Several studies have begun to
investigate the requirement for crosstalk between the epithelium and immune
cells in the regulation of these repair processes during recovery.  This model is a
useful tool to address how cell signaling pathways modulate acute inflammation
and crypt injury, as well as the role of signaling molecules in re-epithelialization of
colon following epithelial damage.
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YAMC cells
Most immortalized cell culture models of the colon epithelium are
transformed cell lines originating from colon adenocarcinomas.  To better
understand the role of signaling pathways in the normal colon epithelium, the
conditionally-immortalized young adult mouse colon (YAMC) cell line was used in
this study.  YAMC cells were isolated from a transgenic mouse expressing a
simian virus 40 (SV40) large T-antigen with a temperature-sensitive mutation
(tsA58) driven by a major histocompatibility complex (MHC) H-2kb class I
promoter (133,134).  Interferons increase SV40 T-antigen expression, therefore
the promoter was engineered with an interferon-inducible element (134).  These
cells are immortalized at 33ºC in the presence of interferon-g; when the cells are
shifted to 37ºC in the absence of interferon, the SV40 T-antigen is inactivated.
Under these non-permissive conditions, YAMC cells behave like primary cells,
including onset of senescence and cell death after several passages.  Previous
results from our laboratory have characterized TNF and MAPK signaling in
YAMC cells and have demonstrated that this cell model reproduces proliferative
and apoptotic responses similar to conditions observed in vivo, making YAMC
cells an ideal model for these studies (61,135).
Objectives
Previous work in this laboratory has demonstrated that TNF promotes
both pro- and anti-apoptotic signaling pathways in colon epithelial cells.  In the
absence of KSR kinase activity, cell survival signaling downstream of TNF is
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inhibited resulting in TNF-induced apoptosis (136).  Furthermore, KSR activates
Raf both in vitro and in vivo following TNF stimulation.  While studies in other cell
types indicate that Raf is an important mediator of cell survival, little is known
about the role of Raf downstream of cytokine stimulation in the colon epithelium.
The objectives of this study were to investigate the role of Raf in colon epithelial
cell survival in response to acute colitis and in TNFR signaling using intestinal
epithelium-specific Raf knockout mice (Raf KOIE).
For studies describing the role of Raf in inflammation and epithelial
damage (Chapter III), wildtype and Raf KOIE mice were subjected to DSS colitis.
Apoptosis and cell proliferation were measured in these mice following DSS-
induced injury and recovery.  We established an in vitro DSS model to determine
whether Raf expression altered cell survival or activation of anti-apoptotic
signaling pathways in the colon epithelium in response to DSS.  Genetic and
pharmacological inhibitors were used to identify Raf downstream signaling
pathways involved in the observed responses, which were then confirmed in
vivo.
Results from this study demonstrate that Raf protects against epithelial
injury and inflammation and promotes recovery from acute DSS-induced colitis
by both MEK-dependent and –independent pathways.   While we show that Raf
may mediate MEK-dependent ERK activation to promote rapid proliferation of the
colon epithelium, Raf promotes anti-apoptotic signaling in response to injury
through mediating NF-kB nuclear translocation in a MEK-independent manner.
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Since TNF is a primary mediator of DSS-induced epithelial injury (129),
the second objective of this study addressed the requirement for Raf in colon
epithelial cell survival in response to TNF (Chapter IV).  Raf KOIE mice were
utilized to assess colon epithelial cell apoptosis in response to TNF exposure.
Pharmacological inhibitors and RNA interference strategies were used to
investigate the requirement for Raf downstream signaling pathways involved in
cell survival in vitro.  Once these targets were identified, short-term TNF
treatment of Raf KOIE mice confirmed downregulation of the observed pathways
in vivo.  Further examination demonstrated receptor specificity for TNF-induced
cell survival signaling through Raf.
 Our results indicate that activation of TNFR1 stimulates both pro- and
anti-apoptotic signaling pathways in the colon epithelium; however, TNFR1 is
required for cell survival following TNF exposure.  Additional studies with Raf
KOIE mice identified Raf kinase as a key regulator of colon epithelial cell survival
in response to TNF.   Interestingly, Raf promoted NF-kB p65 phosphorylation
and subsequent expression of an NF-kB anti-apoptotic target gene, cIAP1,
independent of MEK signaling to support cell survival.  Taken together, these
results identify a novel pathway in which Raf promotes colon epithelial cell
survival through NF-kB downstream of TNFR1 activation.
Overall, the findings of this study indicate that Raf protects against acute
colitis by promoting colon epithelial cell survival in response to TNF and other
pro-inflammatory stimuli.  In both studies, we reveal a novel anti-apoptotic
signaling pathway in which Raf promotes cell survival through NF-kB,
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independent of MEK activation.  Furthermore, we show that Raf activation
downstream of TNFR1 is required for colon epithelial cell survival in response to
TNF treatment.  In the absence of Raf activation, cells shift toward an apoptotic
program, revealing a mechanism that counterbalances TNF-mediated pro-
apoptotic signaling.
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CHAPTER II
MATERIALS AND METHODS
Mice and genotype confirmation
Transgenic mice and genotyping
Mice harboring a loxP-flanked Raf exon 3 (Raf flx/flx) (gift from Manuela
Baccarini, Vienna Biocenter, Austria) were crossed with mice expressing Cre
recombinase driven by a villin promoter [vilCre (constitutive) or vilCre ERT2
(inducible) mice (gift from Sylvie Robine, Curie Institute, Paris, France)] to
generate Raf intestinal epithelium-specific knockout (Raf KOIE) mice.  All mice
were maintained on a C57BL/6 background. Polymerase chain reaction was
performed to confirm the genotype of homozygous Rafflx/flx; vilCre ERT2 mice.
PCR primers and programs for genotyping are listed in Table 2.1.  TNFR1 and
TNFR2 KO mice (gift from Jacques Peschon, Amgen, Seattle, WA) were mated
to generate TNFR double knockout mice.  C57BL/6 mice were used as wildtype
controls for all TNFR KO mouse experiments.  Immortomice (H-2Kb-tsA58) were
a gift from Robert Whitehead (Vanderbilt University, Nashville, TN).
Tamoxifen injections
 Cre recombination in Raf flx/flx; vilCre ERT2 mice was induced at 6 weeks
of age by intraperitoneal injection of 1 mg tamoxifen (Sigma) daily for 5 days.
Sunflower oil (Sigma) vehicle was used as the negative control.  Tamoxifen was
          Table 2.1: Genotyping primers and PCR programs
primer sequence ref PCR program
Raf DS-lox AACATGAAGTGGTGTTCTCCGGGCGC
Raf US-lox TGGCTGTGCCCTTGGAACCTCAGCAC
(57)
Louvard vilCre F CGCGAACATCTTCAGGTTCT
Louvard vilCre R CAAGCCTGGCTCGACGGCC
(137)
95°C - 5m, 95°C - 30s,
55°C – 30s, 72°C – 1m
(step 2, 35 times), 72°C –
7m, 4°C - hold
Immorto F CAATGCCTGTTTCATGCC
Immorto R CCTGGAATAGTCACCATG
(134) 94°C – 5m, 94°C – 1m,
54°C – 2m, 72°C – 3m
(step 2, 30 times), 72°C –
7m, 4°C - hold
p60B GGATTGTCACGGTGCCGTTGAAG
p60E TGACAAGGACACGGTGTGTGGC
R1KO
p60spe TGCTGATGGGGATACATCCATC
(138) 94°C –3m, 94°C – 20s,
64°C – 30s (-0.5°C per
cycle), 72°C – 35s (step 2,
12 times), 94°C – 20s,
58°C – 30s, 72°C – 2m
(step 5, 25 times), 4°C
hold
Use
for R1
& R2
pgk5’-66 CCGGTGGATGTGGAATGTGTG
p80Kas F AGAGCTCCAGGCACAAGGGCR2KO
p80Kas R AACGGGCCAGACCTCGGGT
(138)
95°C – 4m, 95°C – 1m,
65°C – 1m, 72°C – 30s
(step 2, 34 times), 72°C –
7m, 4°C - hold
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solubilized in sunflower oil by sonication at room temperature for 10 min.
Experiments began ten days after the last tamoxifen injection to allow effective
Cre induction and recombination of the floxed allele.
Mucosal isolation
Mucosal scrapings were prepared by scraping the colon or small intestine
with a glass slide as previously described (139). Protein lysates were extracted in
10 volumes of RIPA buffer (1% triton X-100; 1mM EDTA, 1mM EGTA, 10mM Tris
pH 7.4, 150mM NaCl, 0.1% SDS, 0.2% sodium deoxycholate) with protease and
phosphatase inhibitor cocktails (Sigma) on ice for 10 min.  Epithelial and stromal
fractions were isolated by incubating several 1 cm pieces of opened colon or
small intestine in Cell Recovery Solution (BD Biosciences) for 16 h at 4°C
followed by manual shaking.  The liberated crypts and remaining stroma were
centrifuged separately and lysed with RIPA buffer.  RIPA lysates were cleared by
centrifugation, assayed for protein concentration with DC Protein Assay (Biorad),
and boiled in Laemmli sample buffer (140).
Mouse treatment administration
DSS treatment
A 3% aqueous solution of dextran sulfate sodium (DSS) (36-50 kD, MP
Biomedicals, Solon, OH) was filtered and administered ad libitum to mice for four
days.  A subset of these mice was sacrificed at four days and others were
allowed to recover on regular drinking water for three days.  As a control, some
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mice were given regular drinking water throughout the treatment period.  Mice
were weighed and stool samples tested with guaiac (Hemoccult, Beckman
Coulter) for fecal blood daily.  Colon length was measured at the time of sacrifice.
All animal experiments were performed according to protocols approved by the
Institutional Animal Care and Use Committee at Vanderbilt University.
TNF injections
Mice were injected intraperitoneally (i.p.) with PBS or murine TNF (104 U)
(Peprotech, Rocky Hill, NJ) for 1, 2, or 24 h.  TNF was diluted in 200 ml PBS with
2% fetal bovine serum (FBS) as a carrier protein.  PBS control injections also
contained 2% FBS.
Histological assessment
Mice were euthanized by cervical dislocation under anesthesia.  Swiss-rolled
colon and small intestine were fixed in 10% formalin, paraffin-embedded,
sectioned at 4-6mm, and hematoxylin and eosin (H&E) stained as previously
described (136).  Histology was scored blinded to genotype and condition based
on a scale described by Dieleman et al. (129), which categorizes the severity and
extent of colonic crypt damage and inflammation.  The sections were graded
separately as to the amount and depth of inflammation with a range 0 to 3.  The
amount of crypt damage or regeneration and the percentage involvement in
disease process were graded independently with a range 0 to 4.
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Organ culture
Colons were flushed with PBS and placed in a 10cm dish with DMEM
containing 0.5% FBS and 1% penicillin/streptomycin.  Small rings of colon were
cut from the distal end, opened longitudinally, and cut into three segments.
Using a small, flat spatula, each segment was placed flat with the lumen facing
up in the bottom of a 500mm transwell insert in a 6-well plate (Corning) containing
1.8 ml of media.  2-4 explants were plated per transwell for each condition.
Explants were placed at 37°C for 30 min to equilibrate and treated with TNF (50
ng/ml) for 6 h.  Following treatment, explants were placed in an Eppendorf tube
containing 4% paraformaldehyde in PBS overnight at 4°C.
Cell culture procedures and generation of cell lines
 Cell culture procedures
Conditionally-immortalized young adult mouse colon cells (YAMC) (133)
and TNFR1 KO cells (141) were cultured on rat tail collagen (BD Biosciences)
coated plates and maintained in RPMI 1640 (5% FBS, 100 U/ml
penicillin/streptomycin, 5 mg/ml insulin, 5 ug/ml transferrin, 5 ng/ml selenous acid
(BD Biosciences), and 5 U/ml mouse IFN-g (Intergen) at 33°C (permissive
conditions) in a 5% CO2 humidified incubator.  Prior to all assays, cells were
serum-starved (RPMI 1640, 0.5% FBS, 1% penicillin/streptomycin) and shifted to
37°C (non-permissive conditions) for 16 h.  Cells were treated with murine TNF
100 ng/ml (Peprotech), murine EGF (10 ng/ml) (R&D Systems), or 5% DSS for
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the times indicated. MEK inhibitors, PD98059 (used at 20mM) and U0126 (used
at 10mM), Raf kinase inhibitor (GW5074, 5-20mm), and a PI3-kinase inhibitor,
wortmannin (100nM) were obtained from Calbiochem (Gibbstown, NJ).
Transient transfections
For transient transfections, cells were plated at a density of 2x105 (6-well
plate) or 5x104 (4-well chamber slide, Lab-Tek) and transfected with 50 nmol NF-
kB p65, Raf-1 and/or IkBa siRNA SMARTpool or non-targeting siRNA duplexes
(Dharmacon) with Lipofectamine RNAi/ MAX (Invitrogen) according to
manufacturer’s directions.  The siRNA transfection reagent was incubated with
the cells overnight.
The cDNA clone for dominant-negative Ras (S17N) was obtained from the
Missouri S&T cDNA Resource Center (www.cdna.org) transfected using
Lipofectamine 2000 (Invitrogen) for 6 h, at which point media was replaced with
RPMI growth media.
Generation of TNFR1 addback colon epithelial cells
TNFR1 addback cells were generated by infection of TNFR1 KO colon
epithelial cells (141) with a GFP-containing LZRS retrovirus containing vector
alone or a HA-tagged mouse TNFR1 sequence. Total RNA was isolated from
YAMC cells with Trizol reagent (Invitrogen) and TNFR1 cDNA amplified with a
TaqMan RT-PCR oligo dT kit (Applied Biosystems) using 5’- TGT CAA TTG CTG
CCC TGT C -3’ and 5’- GGG CAT CTA GCA GAA TGG TC-3’ primers.  A C-
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terminal HA epitope tag was added to TNFR1 using 5’- ATG AAT TCA TGG GTC
TCC CCA CCG TGC C G-3’ and 5’-GTCAGG CAT AGT CTG GGA CGT CAT
ATG GAT ATC GCG GGA GGC GGG TCG TG-3’ primers.  Following ligation
into pGEM-T-easy vector (Promega) and digestion with EcoR1 (New England
Biolabs), HA-TNFR1 DNA was ligated into the bi-cistronic LZRS-GFP retroviral
vector (gift from Albert Reynolds, Vanderbilt University, Nashville, TN) digested
with EcoR1 and treated with calf intestinal phosphatase (Promega).  Empty
vector or vector containing the HA-TNFR1 construct was transiently transfected
using Lipofectamine 2000 (Invitrogen) into Phoenix ecotropic viral packaging
cells (142).  Virus containing supernatant was harvested and placed on TNFR1
KO cells for 6 hours, after which media was replaced with regular culture media.
The infection protocol was repeated for three consecutive days and then sorted
based on GFP expression to obtain empty vector or HA-TNFR1 stably-integrated
cell populations.
Generation of conditionally-immortalized Raf flx cell line
Raf flx mice were crossed with an Immortomouse to generate Raf flx/flx;Immorto
mice.  Colon and stomach were isolated from these mice, washed in PBS and
incubated separately in 0.04% sodium hypochlorite in PBS for 15 min.  Following
a rinse with 0.5mM dithiothreitol (DTT)/3mM EDTA in PBS, tissue was incubated
in 25 ml DTT/EDTA solution for 90 min at room temperature.  Organs were then
vigorously shaken in 15 ml PBS to liberate crypts, which were then transferred to
a 15 ml tube and centrifuged at 400 rpm for 5 min to pellet crypts.  Crypts were
38
resuspended in LHC-9 (Invitrogen) with 5 U/ml IFN-g (7.5 ml/stomach, 30
ml/colon) and plated in minimal volume in Cellcoat 24-well plates (Greiner Bio-
one).  After 24 h, 1 ml of media was added to the wells.  When the cells attached,
LHC-9 was replaced with RPMI containing 5% FBS, 1% pen/strep, and
interferon-g and media was changed once a week.  Cells were allowed to
become completely confluent before passage into a larger collagen-coated plate.
Cell lysate preparations
Cell lysates, SDS-PAGE, Western blot analysis
Cell lysates were prepared by scraping in a buffer containing (20mM Tris
pH 7.4, 150mM NaCl, 1mM EDTA, 1% Triton X-100, and 0.1% phosphatase and
protease cocktails (Sigma)).  0.1% sodium dodecyl sulfate (SDS) and 0.2%
sodium deoxycholate was added to lysates from cells used in DSS experiments,
which were then passed through a 27g needle to shear DNA.  Cell lysates were
boiled in Laemmli sample buffer, run on 10 or 15% SDS-polyacrylamide gel
electrophoresis (PAGE), and transferred onto nitrocellulose membrane.
Membranes were blocked with 5% non-fat dry milk in TBS-Tween (0.05%) and
incubated in primary antibody overnight at 4°C.  Polyclonal antibodies used for
Western blot analysis include: anti-Raf-1, B-Raf, E-cadherin, NF-kB p65 (Santa
Cruz, Santa Cruz, CA), phospho-ERK (Promega), IkBa, phospho-p38, phospho-
JNK, phospho-Akt (Cell Signaling, Boston, MA) and HA (Invitrogen).  Monoclonal
antibodies used include: Ras (Upstate) and actin (Sigma).  Following 3 washes
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with TBS-Tween (0.05%) x 5 min, membranes were incubated with secondary
antibodies, anti-rabbit- or anti-mouse-HRP (Cell Signaling).  Membranes were
washed again (3 x 5 min) with TBS-Tween and developed with Western
Lightning (PerkinElmer).
Subcellular fractionation
TNFR1 KO cells containing vector alone or HA-TNFR1 were scraped with
lysis buffer (20mM Tris pH 7.4, 2mM EDTA, 2mM EGTA, 200mM NaCl, and 0.5
mg/ml digitonin including protease and phosphatase inhibitor cocktails) and
incubated on ice for 5 min.  Cytoplasmic extracts were isolated by
ultracentrifugation using a Beckman ultracentrifuge at 55,000 rpm for 40 min at
4°C.  The cytoplasmic fraction was removed, boiled in Laemmli buffer, and the
membrane fraction was incubated with lysis buffer containing 1% Triton X-100 on
ice for 30 min.  Following brief centrifugation at 14,000 rpm for 5 min, the triton-
soluble membrane fraction was removed and boiled in Laemmli buffer.
Activation assays
Ras activation assay
YAMC cells were treated with TNF (100 ng/ml) or EGF (10 ng/ml) for the
times indicated.  Activated Ras was precipitated from whole cell lysates with
agarose conjugated to the Ras-binding domain of Raf (Raf-RBD), which binds
the active GTP-bound form of Ras with high affinity (Upstate, Billerica, MA).
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Agarose beads were washed twice with PBS and boiled in Laemmli sample
buffer.  Western blot analysis was performed to detect Ras bound to the Raf-
RBD beads.
Raf kinase assay
To immunoprecipitate endogenous Raf, 200mg whole cell lysate was pre-
cleared with protein A/G beads (Santa Cruz), incubated with 600ng anti-Raf-1
antibody for 2 h, followed by 35ml protein A/G beads for 1 h.  Immunocomplexes
were washed once in 1M NaCl, twice with PBS, and once in assay dilution buffer.
Kinase assays were performed with Raf-1 kinase assay cascade kit according to
manufacturer’s directions (Upstate).  Briefly, immunoprecipitated Raf was
incubated with 75mM magnesium chloride, 500mM ATP and 0.4 mg inactive
recombinant MEK1 for 30 min at 30°C.  Supernatants were removed and boiled
in Laemmli sample buffer.  Beads were washed once with PBS and boiled in
sample buffer.
Immunocytochemistry
Apoptosis assays
Apoptosis in colon sections was determined by Apoptag in situ oligo ligation
(ISOL) (Chemicon) or immunostaining for active cleaved caspase-3 (Cell
Signaling) (136).  The number of positive-staining cells was determined by
counting the number of positive cells per 100 colonic crypts.  Apoptosis in cell
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culture was assessed by terminal deoxynucleotidyl transferase nick end labeling
(TUNEL) peroxidase staining (Chemicon) or by multi-caspase activation assay
(Biomol) using a cell permeable, sulforhodamine-labeled caspase inhibitor (SR-
VAD-FMK).  Nuclei were stained with 4',6-diamidino-2-phenylindole
(DAPI)(Vector Labs) and percent active caspase- or TUNEL-positive cells were
determined.  Caspase assays were visualized by immunofluorescence on an
Axiovert 200 microscope with Apotome (Zeiss) and TUNEL assays were
visualized using differential-interference contrast (DIC) microscopy on a Leica
DM-IRB microscope.
NF-kB staining
Cells plated in 4-well chamberslides (Lab-Tek, Nunc) were fixed with 1%
freshly de-polymerized paraformaldehyde.  Following post-fixation in ice-cold
methanol, cells were quenched with 3% hydrogen peroxide and solublized with
PBS with 0.2% Triton X-100.  Slides were blocked with 10% goat serum for 20
min, incubated with NF-kB p65 antibody (sc-372, Santa Cruz) for 1 h at room
temperature followed by Cy3-labeled goat anti-rabbit or 7-amino-4-
methylcoumarin-3-acetic acid (AMCA)-conjugated donkey anti-rabbit secondary
antibodies (Jackson Immunoresearch) for 30 min. Slides were mounted using
Vectashield with (Cy3) or without (AMCA) DAPI (Vector Labs) and visualized on
a Leica DM-IRB microscope.
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Immunohistochemistry
Antibodies and staining protocol
Sections were de-paraffinized, rehydrated, and antigen unmasked by boiling
in a citrate-containing buffer (Vector Labs).  Slides were blocked with 10% goat
serum (Zymed) for 30 min and incubated with primary antibody overnight at 4°C.
Antibodies used for immunohistochemistry include: rabbit anti-human Ki-67
(Vector Labs), rabbit monoclonal active caspase-3, phospho-specific antibodies
against ERK, NF-kB p65 phospho-S276 and Ser10 Histone H3 (Cell Signaling).
Slides were incubated with goat anti-rabbit-HRP (Dako) and developed using
DAB substrate kit (Vector Labs).  Slides were counterstained with methyl green
or Mayer’s hematoxylin and viewed on a Nikon Eclipse E800 microscope.
Phospho-ERK staining was quantified by determining the average number of
positive cells per crypt in 50 midcolonic crypts.  The number of NF-kB phospho-
p65-positive cells was determined by counting the number of stained cells per
100 colonic crypts.  The percentage of Ki-67 positive cells was determined by
analysis with the Ariol SL-50 automated image analysis system (Applied Imaging,
San Jose, Calif).  Nuclear Ki-67 staining was processed with the NuclearHighRes
script and cells were classified as positive or negative based on pre-determined
thresholds that evaluate color and intensity of staining, as well as cell size, axis
length, roundness, and compactness.
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X-gal staining
Opened colon or small intestine was fixed in 2% paraformaldehyde for 30
min and washed 3 times in PBS.  Tissue was incubated in a PBS-buffered
solution containing 100mM ferrocyanide, 100mM ferricyanide, 1M MgCl2, 10%
Nonidet P (NP)-40, and 20mg/ml 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (X-gal) overnight at 37°C.  Following X-gal staining, tissue
was washed twice in PBS and Swiss-rolled (136) for sectioning.
In situ hybridization
In situ hybridization followed the protocol as previously described (143).
Antisense 35S-labeled cRNA clones for Lgr5 was generated using T7 RNA
polymerases.  Frozen sections (12mm) were prehybridized and hybridized at
45°C for 4 hours in 50% formamide hybridization buffer containing 35S-labeled
antisense cRNA probe (470bp coding sequence + 300bp 3'UTR) (gift from Hans
Clevers, University of Utrecht, Netherlands).  RNase A–resistant hybrids were
detected by autoradiography.  Sections were post-stained with H&E.
Statistical Analyses
For each experiment, the analysis of variance model was applied to test if
there were any differences in the primary outcome variable.  The overall effect
was tested at 5% level to control the overall type I error rate for the experiment.
Pair-wise comparisons were warranted only when there was an overall effect.
The reported P-values are unadjusted for multiplicity, and they are all below
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adjusted type I error rate for each experiment except for (Figure 4.2).  The
comparisons of interest and their expected direction of the effect were pre-
specified in some cases; otherwise a two-sided test was conducted.  When the
normality assumption did not seem to hold (Figures 3.5 & 4.2), a nonparametric
Kruskal-Wallis test was used instead.   When replicates were available (Figures
3.3 & 3.7), linear mixed-effect models were used to incorporate the additional
information.  The comparisons between the genotypes within a treatment group
were carried out by specifying appropriate contrasts.  All data analyses were
performed using R 2.6.0 (144).
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CHAPTER III
RAF PROTECTS AGAINST COLITIS BY PROMOTING MOUSE COLON
EPITHELIAL CELL SURVIVAL THROUGH NF-kB
Introduction
The intestinal epithelium is a single cell layer that forms the only barrier
between the body and the luminal gastrointestinal contents.  Maintenance of this
cell layer, which turns over every 3-5 days, is dependent upon tight regulation of
proliferation and apoptosis (101,145). Coordinated activation of signaling
molecules involved in the regulation of these processes is essential to maintain
intestinal homeostasis.
In the current study, we test the hypothesis that Raf-1 protects the colon
epithelium during injury and inflammation through activation of an NF-kB-
dependent survival mechanism.  The most widely studied family member of the
Raf family of serine/threonine kinases, Raf-1, is involved in key cellular
processes including proliferation, differentiation, and survival.  Its function is best
understood in the context of the highly conserved mitogen-activated protein
kinase (MAPK) cascade, in which Raf phosphorylates its substrate MEK, which
in turn phosphorylates and activates ERK to promote proliferation and
differentiation.  In addition, Raf regulates MAPK-independent responses to
promote cell survival through various cell context-dependent mechanisms. Raf
appears essential for mammalian development as Raf-1 knockout mice die
between days E9.5-10.5 due to placental defects and Fas-mediated apoptosis in
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the fetal liver (13,54).  In contrast to the Fas-dependent mechanism shown in the
liver, Raf-null macrophages are more sensitive to S. typhimurium-induced
apoptosis through caspase-1 activation (57).  In cardiac-specific Raf knockout
mice, Raf functions as an anti-apoptotic regulator through inhibition of the pro-
apoptotic kinase, ASK-1 (56).
Using the IL-10-/- mouse model, which develops spontaneous colitis
associated with unchecked TNF production (145), we have shown that Raf
threonine phosphorylation is increased during active disease (136).  In the
current study, we utilize a well-characterized model of chemically induced colitis
(127,128,146) to better understand the role of Raf in regulating response to
epithelial injury and mucosal inflammation.  Short-term administration of dextran
sulfate sodium (DSS) induces acute colitis characterized by epithelial damage,
disruption of crypt architecture, and severe infiltration of inflammatory cells
(128,129).  While the exact mechanisms by which DSS induces colitis are not
well characterized, the physiological response involves increased local
production of cytokines (129,130) resulting from increased apoptosis due to loss
of barrier function(147) or failure to recognize bacterial-derived signals(148,149).
Recovery from the acute colitis involves a process during which the damaged
epithelium undergoes hyperproliferation to re-establish the epithelial barrier
(149).
Our data show that intestinal epithelium-specific Raf knockout (Raf KOIE)
mice develop worse colitis than their wildtype counterparts.  Raf KOIE mice
exhibit significantly higher levels of colon epithelial apoptosis and decreased
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enterocyte proliferation following DSS treatment compared to wildtype.
Furthermore, Raf expression is required for ERK and NF-kB activation in DSS-
treated mouse colon epithelial cells.  While MEK activation is insufficient to
promote colon epithelial cell survival, constitutive NF-kB activation rescues DSS-
induced apoptosis in the absence of Raf expression.  NF-kB activation is
attenuated in colon epithelial cells following DSS-induced injury in Raf KOIE mice
compared to wildtype.  These results demonstrate that Raf regulates NF-kB
activation and cell survival in a MEK-independent manner to protect against
intestinal epithelial injury and inflammation.
Results
Raf protects against DSS-induced crypt injury and inflammation.
Raf is a key regulator of cell proliferation and differentiation, and appears
to be an important mediator of cell survival (150).  As Raf-1 deletion is embryonic
lethal (13), we tested the role of Raf in colitis using intestinal epithelium-specific
Raf knockout (Raf KOIE) mice generated by crossing Rafflx/flx mice (wildtype)(gift
from Manuela Baccarini)(57) with mice expressing a tamoxifen-inducible Cre
recombinase under the control of a villin promoter (gift from Sylvie Robine)(151).
To test the efficiency of Cre recombination in the inducible Cre model, vilCre
ERT2 mice were crossed with Rosa26 reporter mice, which express a beta-
galactosidase (LacZ) gene interrupted by a loxP-flanked stop codon.  During
active recombination of the allele, the stop codon is excised permitting LacZ
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expression.  X-gal staining was used to detect LacZ expression in tamoxifen-
treated Rosa26R; vilCre ERT2 mice (Figure 3.1A).  A majority of crypts in both
the colon and small intestine stained LacZ-positive (Figure 3.1B), indicating
successful recombination of the floxed allele in the intestinal epithelium.
Recombination of the Raf allele in the inducible villin-Cre ERT2 system
was detected by Western blot analysis of isolated epithelial and stromal fractions.
Raf expression was effectively knocked out in the intestinal epithelium, but not
the stroma, of both the colon and small intestine in Raf KOIE mice (Figure 3.2). In
contrast, B-Raf expression in the intestinal epithelium was not affected.
While other conditional Raf knockout mice have striking phenotypic
changes (56), Raf KOIE mice show normal architecture of the intestinal and
colonic epithelium (Figure 3.3A).  Unchallenged Raf KOIE mice also display no
basal defects in cell proliferation or migration up the crypt-villus axis (data not
shown).  B-Raf expression is detectable in the colon epithelium, both in cultured
cells and in vivo, indicating that regulation of Raf signaling may be functionally
redundant in the context of cell maintenance.
Injury models have been used to delineate the requirement for specific
gene products and/or signaling pathways in response to tissue damage and
disease.  To assess the role of Raf in intestinal injury and inflammation, 3% DSS
was administered via drinking water to 8-week-old wildtype and Raf KOIE mice.
Mice received either water alone (control) or 3% DSS for four days to induce
colitis.  Following four days of acute injury, some DSS-treated mice were
Figure 3.1:  Inducible villin-Cre ERT2 expression induces LacZ 
recombination.  (A) Whole mount images of colon, distal small intestine (DSI), 
proximal small intestine (PSI) from Rosa26R; vilCreERT2 mice 2 weeks after 
injection with oil or tamoxifen stained with X-gal.  (d, distal; p, proximal)  
(B) Representative images of X-gal-stained colon and small intestine from 
tamoxifen-injected mice. 
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Figure 3.2:  Raf expression is absent in inducible Raf intestinal epithelium-
specific knockout mice.  Epithelial and stromal fractions were isolated from the  
colon and small intestine of oil- or tamoxifen-injected Raf flx/flx; villin-Cre mice.
Western blot analysis was performed with antibodies against Raf-1, B-Raf, 
E-cadherin, and actin.  Raf flx/flx mice were a gift from Manuela Baccarini
(Vienna Biocenter, Austria) and villin-Cre mice were a gift from Sylvie Robine
(Curie Institute, Paris, France).
50
A water injury 3d recovery
w
ild
ty
p
e
R
af
 K
O
IE
w
ild
ty
p
e
R
af
 K
O
IE
20X
4X
15
10
5
0
in
ju
ry
/i
n
fla
m
m
at
io
n
 s
co
re
P=0.002
 wildtype     Raf KOIE  wildtype     Raf KOIE  wildtype     Raf KOIE
water injury 3d recovery
cr
yp
t 
h
ei
g
h
t 
(µ
M
)
0
100
200
300
400
500
wildtype  Raf KOIE wildtype  Raf KOIE wildtype  Raf KOIE
water injury 3d recovery
P<0.001
B C
Figure 3.3:  Raf KOIE mice exhibit increased crypt injury and inflammation 
resulting from colitis.  (A) H&E staining of colon sections from wildtype and 
Raf KOIE mice treated with water, 3% DSS for 4 days, or 4 days plus a 3 day 
recovery period.  Scale bar = 500µm or 125µm  (B) Combined scores grading 
severity of inflammation and extent of crypt damage in wildtype or Raf KOIE mice 
following DSS treatment. Bars represent the mean value.  (C)  Crypt height in 
wildtype and Raf KOIE mice following DSS treatment.  Bars represent the median.
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maintained on water alone for a three-day recovery period.  In response to DSS,
both wildtype and Raf KOIE colonic epithelium suffered loss of crypt architecture
and mucosal inflammation primarily in the midcolon (Figure 3.3A).  The proximal
and terminal colon showed little crypt damage.  However, injury and inflammation
scores were significantly higher in Raf KOIE mice (P=0.002) (Figure 3.3B).   Raf
expression contributed to attenuation of DSS-induced inflammatory response as
Raf KOIE mice had increased inflammatory infiltrate, greater depth of
inflammation, and higher percent colon involved in inflammation following acute
injury.  We observed that Raf KOIE mice were 2.5 (95% CI (1.2,5.4)) times more
likely to have blood present in the stool compared to wildtype during days 2-4 of
DSS treatment (data not shown).  Wildtype mice showed increased crypt height
compared to Raf KOIE during recovery (P<0.001), whereas both genotypes had
shortened crypts following injury (Figure 3.3C).
No clinical signs of colitis were apparent in wildtype or Raf KOIE mice after
4 days of DSS treatment.  To assess if loss of Raf resulted in clinical differences
in response to a more severe injury, the length of DSS adminstration was
extended to 8 days.  In response to prolonged DSS exposure, both wildtype and
Raf KOIE mice demonstrated extensive crypt injury and inflammation (Figure
3.4A).  Interestingly, mice began losing weight at treatment day 6, and by day 8,
Raf KOIE mice had lost significantly more weight than their wildtype counterparts
(Figure 3.4B)(P=0.023).  Furthermore, Raf KOIE mice had decreased colon
length compared to wildtype mice, another indication of colonic inflammation
(Figure3.4C)(P<0.01).  These data indicate that Raf expression in the intestinal
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Figure 3.4: Loss of Raf expression results in worsened clinical signs of 
colitis.  (A)  H&E staining of wildtype and Raf KOIE mice following 8 day DSS 
treatment.  Scale bars = 500µm and 250µm  (B)  Graphical representation of 
the average percent of weight loss for wildtype and Raf KOIE mice compared 
to the weight at the start of DSS treatment.  (C) Colon length is represented
in a ratio compared to the starting weight of mice prior to DSS administration.  
Horizontal bars represent the mean value.
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epithelium protects against epithelial damage and the associated inflammatory
response after acute DSS treatment.
Raf expression confers intestinal epithelial cell survival during DSS colitis.
Maintenance of the intestinal epithelial barrier is dependent upon the tight
regulation of proliferation and apoptosis.  To assess whether the increased
severity of crypt damage in Raf KOIE mice was due to decreased intestinal
epithelial survival, we measured DSS-induced apoptosis in intact crypts
surrounding regions of ulceration in wildtype and Raf KOIE mice by ISOL (Figure
3.5).  Acute DSS exposure induced colon epithelial cell death in both wildtype
and Raf KOIE mice; however, apoptosis was significantly higher in the absence of
Raf expression (P=0.046).  These data were confirmed by active-caspase-3
staining (P=0.008, data not shown).  Taken together, the results indicate that Raf
plays an anti-apoptotic role during DSS-induced injury and inflammation.
Raf promotes hyperproliferation during epithelial regeneration.
Previous studies have demonstrated that hyperproliferation of enterocytes
occurs to regenerate damaged epithelium during recovery from acute colitis
(149).  To determine the role of Raf in this phenomenon, we examined colonic
epithelial cell proliferation during the recovery phase of DSS colitis in wildtype
and Raf KOIE mice by immunohistochemistry for Ki-67 and phospho-histone H3.
During recovery, wildtype mice have long, highly proliferative colonic crypts
compared to Raf KOIE, which display fewer proliferative cells in shorter, poorly
Figure 3.5:  Raf protects from apoptosis in response to damage in the 
intestinal epithelium.  (A) Apoptotic cells were detected by in situ oligo ligation 
(ISOL) in colon sections of DSS-treated wildtype and Raf KOIE mice.  
Scale bar = 50µm  (B) The average number of ISOL-positive cells were 
represented graphically.  Horizontal lines represent the median for each data set.
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organized crypts (Figure 3.6A).   Quantification of Ki-67 positive cells
demonstrated hyperproliferation in the midcolon of wildtype mice in response to
initial injury  (P=0.036, P=0.003); in contrast, the number of proliferating cells in
Raf KOIE mice during recovery is similar to that of mice receiving water alone
(Figure 3.6B).  The number of cells per hemicrypt was also increased in wildtype
mice compared to Raf KOIE mice (P<0.001) (Figure 3.6C).  In situ hybridization
for Lgr5 demonstrated that Raf expression does not drastically effect the stem
cell population in unchallenged mice or during epithelial regeneration (Figure
3.7).
To determine the role of canonical Raf signaling in cell proliferation, we
assessed the localization of active ERK in wildtype and Raf KOIE mice during
recovery.  In both wildtype and Raf KOIE untreated mice, phosphorylated ERK is
localized to the nucleus of differentiated cells lining the surface epithelium (Figure
3.8A).  In the hyperproliferating crypts of recovering wildtype, but not Raf KOIE,
mice active ERK is visible as nuclear and diffuse cytoplasmic staining throughout
the crypt axis (P=0.001) (Figure 3.8B).  Western blot analysis confirmed the
absence of Raf expression in the epithelium following injury, eliminating the
possibility that Raf signaling is restored during recovery (data not shown). These
data indicate that in addition to playing a protective anti-apoptotic role, Raf is
required for rapid epithelial regeneration following DSS colitis.
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Figure 3.6:  Raf is required for the epithelial hyperproliferative response 
following DSS-induced injury.  (A) Proliferating cells were detected by Ki67 and
phospho-histone H3 staining in colon sections of wildtype and Raf KOIE mice 
during recovery from DSS-induced colitis.  (B) The percentage of Ki67-positive 
cells in the midcolon are represented graphically.  (C)  The number of cells per 
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Figure 3.7: Raf expression does not affect the number of Lgr5-positive
cells in the colon epithelium.  In situ hybridization was performed for Lgr5 
in colon sections of wildtype and Raf KOIE mice following water treatment and 
3 day recovery following DSS-induced injury.  Darkfield images show Lgr5 
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Raf protects from DSS-induced apoptosis through NF-kB activation.
To explore the underlying mechanism of Raf promoting colon epithelial
cell survival during injury and inflammation, we utilized RNA interference in cell
culture to assess the role of Raf on the activation of pro- and anti-apoptotic
signaling pathways.  YAMC cells were transfected with non-targeting or Raf-1
siRNA and then treated with 3 or 5% DSS for 7 h.  A time course was performed
to determine at which time point, DSS induced cell loss (data not shown).
TUNEL staining showed that apoptosis was significantly increased in response to
5% DSS in YAMC cells transfected with Raf siRNA compared to non-targeting
siRNA (P=0.03) (Figure 3.9A&B).  To confirm that these apoptotic effects were
specific to our DSS treatment, siRNA-transfected YAMC cells were treated with
5% high molecular weight DSS (500kD), which did not induce colitis or intestinal
epithelial apoptosis in wildtype or Raf KOIE mice (data not shown).  Similar to our
in vivo findings, high molecular weight DSS treatment did not induce significant
apoptosis in cell culture compared to treatment with 5% low molecular weight
DSS (P=0.01)(Figure 3.10).  IL-13 was used as a negative control to demonstrate
Raf-independent apoptosis (152).
By five hours, a majority of DSS-treated cells underwent apoptosis and
detached from the plate.  To address the mechanisms involved in this effect,
lysates from cells treated for time points leading up to five hours were subjected
to Western blot analysis for pro- and anti-apoptotic signaling pathways.  TNF,
which promotes both cell survival and death in these cells (135), served as a
positive control.  Raf siRNA is specific to Raf-1 and does not block expression of
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Figure 3.9:  36-50 kD DSS induces apoptosis in vitro.  Transfected cells 
were treated with IL-13 (10 ng/ml), 5% high (500kD) or low (36-50kD) molecular 
weight DSS for 7 h and the number of apoptotic cells were quantified by 
TUNEL assay. 
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Figure 3.10:  Raf is required for DSS-induced ERK and NF-κB activation.  
Non-targeting or Raf siRNA-transfected YAMC cells were treated with 5% DSS 
for the times indicated.   Western blots with whole cell lysates from DSS- or 
TNF- (100 ng/ml, 15 min) treated siRNA-transfected cells were probed for Raf, 
B-Raf, phospho-ERK, IκB, phospho-Akt, phospho-p38, phospho-JNK, and actin 
antibodies.
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B-Raf isoform (Figure 3.11).  5% DSS stimulated the pro-apoptotic pathways p38
and JNK regardless of Raf expression.  In contrast, DSS-induced ERK
phosphorylation and IkB degradation required Raf (Figure 3.11).  Interestingly,
DSS did not induce Akt phosphorylation, suggesting that in this model Raf is only
required for ERK and NF-kB activation.
To determine whether Raf activation of MEK/ERK signaling or NF-kB
mediates cell survival in response to DSS, TUNEL was performed on YAMC cells
either co-treated with a MEK inhibitor, PD98059 (20mM) or U0126 (10mM), and
5% DSS for 7 h or transfected with siRNA directed against IkBa to induce
activation of NF-kB.  While both MEK inhibitors blocked ERK activation in
response to DSS (Figure 3.12B), neither increased susceptibility to DSS-induced
apoptosis (Figure 3.12A), indicating that MEK activation is not required for cell
survival after DSS exposure.  Inhibition of MEK using U0126 did not block DSS-
induced apoptosis in the absence of Raf expression (Figure 3.13) further
confirming that Raf-mediated cell survival occurs independent of MEK activation.
Using siRNA to knock down expression of NF-kB p65, Raf and/or IkBa,
we showed that NF-kB signaling is involved in Raf-induced cell survival (Figure
3.14&15).  Deletion of IkBa promoted constitutive translocation of NF-kB p65
subunit to the nucleus (Figure 3.14).   Furthermore, DSS-induced NF-kB p65
translocation was partially inhibited in the absence of Raf. Following treatment
with 5% DSS for 7 h, TUNEL staining shows that either absence of NF-kB p65 or
Raf absence promotes DSS-induced apoptosis to a similar extent (Figure
3.15)(P=0.005, P=0.002).  Furthermore, constitutive activation of NF-kB with
Figure 3.11:  Raf is required for intestinal epithelial cell survival in response
to DSS.  YAMC cells were transfected with non-targeting or Raf siRNA and 
treated with 3 or 5% DSS for 7 h.  (A) Apoptosis was determined by TUNEL 
assay (Scale = 100µm) and (B) the percent of TUNEL-positive cells was 
assessed.  
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Figure 3.12:  MEK activation promotes DSS-induced apoptosis.  
YAMC cells were treated with MEK inhibitors, PD98059 (20 µM) or U0126 
(10 µM), and 5% DSS for 7 h.  (A) Apoptosis was detected by TUNEL and 
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absence of Raf.  YAMC cells were transfected with non-targeting or Raf siRNA 
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DSS treatment.  (A) Western blot analysis was performed on NF-κB p65, Raf or 
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Figure 3.15:  NF-κB activation rescues DSS-induced apoptosis in the 
absence of Raf expression.  Apoptosis in 5% DSS-treated NF-κB p65, Raf 
and/or IκBα siRNA-transfected YAMC cells was assessed by TUNEL assay.
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IkBa siRNA rescues Raf siRNA-transfected cells from DSS-induced apoptosis.
This requirement for Raf in NF-kB activation was confirmed in vivo, as nuclear
NF-kB p65 was increased in the colon epithelium following DSS injury in
wildtype, but not Raf KOIE mice (Figure 3.16).  Taken together, these data
demonstrate that Raf regulates NF-kB activation in a MEK-independent manner
to promote colon epithelial cell survival in response to injury.
Discussion
In this study, we demonstrate a MEK-independent requirement for Raf in
anti-apoptotic signaling in response to colonic epithelial injury.  DSS-induced cell
damage promotes Raf-dependent activation of both MEK/ERK/MAPK and NF-kB
signaling in mouse colon epithelial cells both in vivo and in vitro.  In the absence
of Raf expression, DSS-induced apoptosis is increased in cell culture and in
intact colon epithelium.  Interestingly, ERK activation promotes apoptosis in
response to DSS-induced injury, suggesting that this pathway is not involved in
Raf-stimulated cell survival.  However, Raf may directly or indirectly promote
ERK activation to enhance epithelial cell proliferation during recovery from colitis.
In contrast, loss of NF-kB p65 expression induced apoptosis following DSS
exposure, and constitutive activation of NF-kB signaling rescued Raf-null colon
epithelial cells from apoptosis.  In vivo studies indicate that NF-kB nuclear
translocation is decreased in Raf KOIE mice following DSS-induced injury
Figure 3.16:  Raf promotes NF-κB activation in the colon epithelium in 
response to DSS-induced injury.  Representative images are shown of 
immunofluorescence for NF-κB p65 (green), E-cadherin (red) and DAPI-stained 
nuclei (blue) in colon sections of wildtype and Raf KOIE mice following water 
treatment or DSS-induced injury.  Scale bars = 20µM
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compared to wildtype.  Thus, MEK-independent Raf anti-apoptotic signaling is
mediated through NF-kB to protect against acute colitis.
Raf KOIE mice develop more severe colitis, with more extensive crypt
damage and inflammation during acute injury, than wildtype mice.  Furthermore,
Raf prevents colon epithelial cell apoptosis during DSS colitis.  To address the
molecular mechanism by which Raf promotes cell survival, we used a cell culture
model of DSS treatment previously used to characterize Caco-2/bbe-mediated
barrier function (153).  Knockdown of Raf expression decreased both ERK and
NF-kB activation in response to DSS (Figure 3.8).  Given previous reports of
MEK/ERK anti-apoptotic function (136,154), we hypothesized that Raf activation
of this pathway was responsible for promoting cell survival following DSS
treatment.  However, our findings show that MEK activity is required for DSS-
induced apoptosis (Figure 3.12).  These data are consistent with previous studies
showing ERK promotes hydrogen peroxide-induced cell death by activating
caspase-3 in renal epithelial cells (155,156).  In the same cell type, E. coli toxin
promoted ERK-induced apoptosis in a caspase-independent manner (157).
These results are consistent with in vivo experiments using the MEK inhibitor,
U0126, showing decreased inflammation and epithelial apoptosis during
cisplatin-induced acute renal failure (158).  Our findings expand the known
functions of MAPK signaling in the colon epithelium by demonstrating that Raf
stimulates colon epithelial cell proliferation in response to injury, and that ERK
signaling triggers a pro-apoptotic response to DSS.  Thus, Raf promotes colon
epithelial cell survival in a MEK-independent manner.
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In addition to directly or indirectly activating MEK/ERK signaling, Raf
expression is required for IkB degradation and subsequent NF-kB activation
following DSS exposure (Figures 3.11, 3.14 and 3.16).  Several studies have
targeted NF-kB as a potential therapeutic target for IBD; however, NF-kB
promotes both apoptosis and cell survival in a cell context-dependent manner.
NF-kB p65 antisense oligonucleotides decreased the severity of colitis in
trinitrobenzene sulfonic acid and IL-10-/- colitis models (159).  Mice deficient in
A20, a cytoplasmic ring finger protein that inhibits NF-kB activity, develop
spontaneous colitis at 4 weeks of age (160).  In contrast, disruption of NF-kB
activation specifically in the intestinal epithelium demonstrates that NF-kB has a
protective effect against apoptosis and colitis.  Intestinal deletion of IkB kinase b
(IKKb), one of three IKK isoforms involved in NF-kB activation, increases
susceptibility to DSS colitis and apoptosis, yet targeted deletion of IKKb in
myeloid cells did not affect cell survival (126).  Mice deficient for intestinal
epithelial cell NEMO (IKKg) develop spontaneous colitis and NEMO-deficient
intestinal epithelial cells are highly susceptible to TNF-induced apoptosis (161).
RelA-intestinal epithelial-deficient mice are more sensitive to DSS colitis and with
increased epithelial apoptosis in response to injury (162), further supporting a
role for NF-kB in cell survival in response to injury and inflammation.
In these studies we show that Raf regulates NF-kB activation in a MEK-
independent manner in intestinal epithelial cells (Figures 3.12 & 3.15).  Our
findings are supported by previous reports that a Raf mutant (Raf-BXB T481A)
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which cannot bind MEK, and thus blocks ERK activation, still activates a NF-kB
reporter construct in NIH 3T3 cells (50).
 Baumann et al. demonstrated that NF-kB is required for Raf-mediated
oncogenic transformation of fibroblasts.  In T-cells, Raf promoted activation of a
NF-kB reporter gene independent of MEK/ERK activation, but dependent upon
Raf kinase activity (163).  In our study, IkB degradation, NF-kB p65 nuclear
translocation, and colon epithelial cell survival in the presence of DSS were Raf-
dependent.  We hypothesize that Raf may function in conjunction with other
known upstream regulators of NF-kB signaling such as NIK or IKK, since
knockdown of Raf expression did not completely block NF-kB p65 nuclear
translocation (Figure 3.14).  Thus, these data provide the first evidence that Raf
mediates NF-kB activation using a disease model and in vitro, using non-
transformed cells.
During recovery from initial injury, we found that wildtype and Raf KOIE
mice injury and inflammation scores were similar.  This may be attributed to the
significant increase in apoptosis seen in both wildtype and Raf KOIE mice during
remodeling of the injured colon epithelium (Figure 3.5).  In fact, increased
infiltrating inflammatory cells appear necessary for epithelial regeneration in the
DSS model.  Pull et al. showed that activated macrophages are required to
promote regeneration of the damaged epithelium by eliciting colon epithelial
progenitor cell responses (164).  No apparent difference in the number of
macrophages (anti-F4/80) or neutrophils were detected by immunohistological
staining between wildtype and Raf KOIE mice following injury or recovery (data
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not shown).  Although similar defects in injury repair have been reported in the
DSS colitis model for TLR4 and Cox-2 knockout mice (148,149), we found no
change in expression of either protein in the colon in the absence of Raf or in
response to DSS (data not shown).
The proliferation defect during recovery in Raf KOIE mice is likely due to
impaired MEK-dependent pathways in the colonic crypt.  Increased levels of
phosphorylated ERK are present in the cytoplasm of wildtype mouse cells
throughout the crypt axis during recovery, whereas activated ERK is restricted to
the surface epithelium in Raf KOIE mice similar to untreated mice (Figure 3.8).
These data are consistent with reports in various cell types in which transient
ERK activation in the cytoplasm promotes proliferation, while sustained ERK
activation in the nucleus induces growth arrest and differentiation (135,165,166).
Thus, Raf-1 specific activation of MEK may be required for maximal proliferation
following DSS-induced injury.  Supporting this conclusion, a recent report by
Scholl et al. shows that even in the presence of activated Raf, loss of MEK1/2
expression inhibits hyperproliferation in the mouse epidermis (167).  Taken
together, these findings suggest that Raf directly or indirectly regulates
MEK/ERK-mediated colon epithelial proliferation in response to injury.
Overall, these findings establish a novel role for Raf kinase in both the
anti-apoptotic and hyperproliferative epithelial responses to injury in the colon.
Our model suggests Raf initiates MEK-independent NF-kB activation to reduce
the apoptotic response to injury, while potentially increasing MEK-dependent
ERK activation to enhance proliferation and rapidly restore the colon epithelium
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during acute colitis. Given the link between these responses and colitis-
associated carcinogenesis, our findings suggest future studies are needed to
better define the role of Raf-1 in response to chronic injury.  In this regard,
pharmacological inhibition of Raf signaling is a current target of cancer
therapeutic drug development (168).  These findings have important implications
for human disease, as patients with inflammatory bowel disease are at an
increased risk to develop colon cancer with greatest risk to those with repeated
cycles of inflammation (169).  A key challenge is to understand how Raf activates
NF-kB-dependent pathways in intestinal epithelial cells following injury and to
determine if there is a pathogenic role in colitis-carcinogenesis transition.
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CHAPTER IV
TNFR1 PROMOTES TNF-MEDIATED MOUSE COLON EPITHELIAL CELL
SURVIVAL THROUGH RAF ACTIVATION OF NF-kB
Introduction
In the gastrointestinal tract, increased levels of tumor necrosis factor (TNF)
promote the pathogenesis of several diseases including, inflammatory bowel
disease (IBD)(170,171), celiac disease (172), graft-versus-host disease (173),
and non-steroidal anti-inflammatory drug (NSAID) enteropathy (174).  Clinical
studies indicate that circulating serum levels of TNF are increased in Crohn’s
disease patients (175), and neutralizing TNF monoclonal antibodies have been
shown to reverse disease activity in IBD patients (115,116), further supporting
the pathogenic role of TNF in the colon epithelium. The exact role of TNF
signaling in the colon epithelium remains unclear as TNF overexpression causes
inflammatory bowel disease in a mouse model (176), while mice deficient in TNF
production develop worse colitis in response to dextran sulfate sodium (DSS)
than their wildtype counterparts (177).  Therefore, further study is required to
delineate the role of TNF signaling in the colon epithelium.
TNF binds two cell surface receptors: TNF receptor (R)1 (p55/60) or TNFR2
(p75/80) (reviewed in (178,179)), with a higher ligand affinity for TNFR2
(180,181).  Each receptor promotes different cellular responses in a cell context-
dependent manner (182,183).  In the colon epithelium, TNF signals through
TNFR2 to promote proliferation (184) and migration (185), whereas sustained
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activation of mitogen-activated protein kinase (MAPK) signaling through TNFR1
induces growth arrest (135).  In contrast, in intestinal myofibroblasts, TNFR2
stimulates proliferation through MAPK activation (186).  Although it is known that
TNFR1 can promote apoptosis through death domain-dependent signaling (81),
several reports indicate that TNF promotes anti-apoptotic signaling pathways in a
cell context-dependent manner (86,136,187-189).  Considering this single ligand
induces signaling both cell survival and cell death, cell specific signal
transduction regulation must occur to determine at which point a cell irreversibly
progresses toward apoptosis.
TNF stimulation is insufficient to induce apoptosis in a number of cell
types, demonstrating a complex balance between cell survival and apoptotic
pathways.  For example, in the colon epithelial cells, TNF-induced anti-apoptotic
signaling requires the serine/threonine kinase, kinase suppressor of Ras (KSR),
which promotes MAPK, Akt, and NF-kB activation.  Loss of KSR shifts cells
toward an apoptotic program following TNF exposure (136).  These findings
suggest that during the maintenance of epithelial homeostasis, TNF tightly
modulates the apoptotic response by inducing both pro- and anti-apoptotic
pathways.
Raf-1, the only well-characterized substrate of KSR (32,136,190), is a
serine/threonine kinase which regulates several cellular functions from
proliferation and differentiation to survival (150).  Canonical Raf activation
through receptor tyrosine kinase signaling is well-characterized (191); however,
little is known about the mechanism of Raf activation in cytokine signaling.  A
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requirement for Raf in cell survival was demonstrated in Raf knockout mice,
which are embryonic lethal due to Fas-mediated hepatocellular apoptosis and
placental defects (11,53). Conditional tissue-specific Raf deletion shows that Raf
is required for both cardiomyocyte, through the regulation of apoptosis signal-
regulating kinase 1 (ASK1) (56), and macrophage survival following S.
typhimurium infection (57).  Furthermore, in inducible intestinal epithelium-
specific Raf knockout mice (Rafflx/flx; villin-Cre ERT2), Raf enhances colon
epithelial cell survival during acute colitis through an nuclear factor k-B (NF-kB)-
dependent mechanism (Edelblum and Polk, unpublished observations).
TNF is a potent inducer of NF-kB, which regulates cell survival and the
production of inflammatory cytokines (192). NF-kB p50/p65 dimers are
sequestered in the cytoplasm through binding interactions with inhibitor of kB
(IkB). TNF induces phosphorylation of IkB by the IkB kinases (IKK), leading to
IkB ubiquitination and proteasomal degradation, and subsequent NF-kB nuclear
translocation.  In the nucleus, NF-kB is phosphorylated and functions as a
transcription factor to induce expression of both pro- and anti-apoptotic target
genes, including Bcl family members and inhibitor of apoptosis proteins
(IAPs)(82). Although NF-kB promotes both cell survival and cell death in a cell
context-dependent manner (192),  conditional inactivation of the NF-kB pathway
shows a requirement for NF-kB in colon epithelial cell survival following
inflammatory stimuli (126,161).
In this report we show that TNFR1 is required for colon epithelial cell
survival and anti-apoptotic signaling following exposure to TNF.  Our data
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indicate that TNF stimulation promotes activation of Raf in colon epithelial cells
via a novel Ras-independent mechanism.  Through the generation of an
intestinal epithelium-specific knockout mouse (Raf KOIE), we demonstrate that
Raf expression is required for TNFR-induced cell survival both in vivo and in
vitro.  While inhibition of the Raf kinase target, MEK, had no effect on TNF-
stimulated cell death, blockade of a novel Raf-1 target, NF-kB activation, resulted
in increased apoptosis.  Consistent with this observation, constitutive activation
of NF-kB rescues mouse colon epithelial cells from TNF-induced apoptosis in the
absence of Raf.  Raf was required for TNF-induced NF-kB p65 phosphorylation
and cIAP1 expression in vivo, suggesting that Raf mediates colon epithelial cell
survival through activation of NF-kB in a MEK-independent manner downstream
of TNFR1.
Results
TNFR1 is required for cell survival in the presence of TNF.
Previous findings from our laboratory indicate that TNFR2 promotes
proliferation and migration responses in vitro, whereas TNFR1 activation inhibits
both of these processes (185).  To further delineate the role of TNFR1 in the
intestinal epithelium, wildtype, TNFR1 KO, TNFR2 KO, and TNFR 1/2 double
knockout (DKO) mice were injected i.p. with PBS or TNF (104 units).  After 24 h,
mice were sacrificed and apoptosis was assessed by in situ oligo ligation (ISOL).
TNFR1 knockout mice exhibited a significant increase in apoptosis following TNF
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treatment compared to wildtype (Figure 4.1) (P<0.01).   Neither TNFR2 KO nor
DKO mice showed enhanced to TNF-induced apoptosis.
These findings were confirmed in a TNFR1 KO cell culture model.  TNFR1
KO colon epithelial cells were either mock infected or infected with retrovirus
expressing HA-tagged TNFR1, and then treated with TNF (100 ng/ml).  Following
6 h TNF exposure, TNFR1 KO cells showed higher levels of apoptosis compared
to the untreated control and TNFR1 addback cells treated with TNF (Figure 4.2).
To investigate the signaling pathways underlying this response, TNFR1 KO and
addback cells were exposed to TNF for 15 min.  Western blot analysis of whole
cell lysates demonstrated that in the absence of TNFR1, TNF-induced activation
of pro- and anti-apoptotic signaling pathways was not blocked; however, re-
expression of TNFR1 in these cells restored activation of these signaling
pathways (Figure 4.3A).  Activation of caspase-3 and 9 were detected in TNFR1
KO cells following longer TNF exposure, caspase activation was absent in cells
re-expressing the receptor (Figure 4.3B).  Subcellular fractionation was used to
confirm expression of HA-tagged TNFR1 at the plasma membrane of the TNFR1
addback cells (Figure 4.3C).  These data indicate that TNFR1 is required for
acute TNF stimulation of both pro- and anti-apoptotic signaling in colon epithelial
cells at the times studied, but in the absence of TNFR1 the balance of TNF
signaling shifts towards cell death.
Figure 4.1: TNFR1 mediates colon epithelial cell survival signaling.  
TNFR1, TNFR2, and TNFR double knockout (DKO) mice were treated with TNF 
for 24 h.  (A) Apoptosis was assessed by ISOL staining (Scale bar = 62µM) and 
(B) quanitified as the number of positive cells per 100 crypts.  Bars represent the 
mean.  
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Figure 4.2:  TNFR1 is required for TNF-mediated cell survival in vitro.  
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treated with TNF (100 ng/ml) for 6 h.  Scale bar = 100µM (B)  Graphical 
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Figure 4.3:  TNF-induced activation of TNFR1 promotes both pro- and anti-
apoptotic signaling pathways.  (A)  Western blot analysis of TNFR1 knockout 
cells expressing vector or TNFR1 treated with TNF (100 ng/ml) for 15 min.  
Whole cell lysates were blotted for phospho-MAPK, IκB, phospho-Akt, phospho-
p38, phospho-JNK, and actin.  (B)  Western blot analysis was performed on 
TNFR1 knockout cells expressing vector or TNFR1 following 30 min-6 h TNF 
exposure for cleaved poly-ADP ribose polymerase (PARP), active caspase-3 
and -9.  Total caspase-9 was used as a loading control. (C) Western blot analysis
for HA was performed on cytoplasmic and membrane fractions from TNFR1 
knockout cells expressing vector or TNFR1.  EGFR was used as a positive
control for membrane proteins.
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TNF promotes MAPK activation in a Ras-independent manner.
Raf kinase activation requires membrane translocation and activation by
phosphorylation at several sites (29).  The canonical mechanism by which Raf is
recruited to the membrane involves Ras GTPase (193).  To assess whether TNF
stimulation promotes Ras activation in colon epithelial cells, YAMC cells were
treated with TNF or EGF (Figure 4.4A) and the level of activated Ras determined
by Ras-GTP pulldown assay.  Western blot analysis from the pulldown assay
indicated that EGF, but not TNF, strongly stimulated Ras activation, suggesting
that Ras is not involved in TNF activation of MAPK.  To test this, YAMC cells
were transfected with a dominant-negative H-Ras construct (S17N), which blocks
the access of Ras guanine nucleotide exchange factors (194).  Consistent with
Ras activation patterns, expression of dominant-negative Ras blocked EGF-, but
not TNF-stimulated ERK activation (Figure 4.4B).  These findings demonstrate a
novel mechanism by which ERK is activated in a Ras-independent manner.
To confirm that TNF promotes Raf activity in our system, an in vitro kinase
assay was performed with endogenous Raf immunoprecipitated from YAMC cells
following TNF or EGF treatment. Raf isolated from TNF-stimulated cells
phosphorylated recombinant MEK in vitro, although to a lesser extent than with
EGF treatment (Figure 4.5).  Taken together, these data demonstrate that TNF
promotes MAPK activation in a Ras-independent manner.
Figure 4.4:  TNF promotes MAPK activation in a Ras-independent manner.  
(A) YAMC cells were treated with TNF or EGF and activated Ras was pulled 
down using Raf-RBD-conjugated agarose beads.  Western blot analysis was 
used to detect GTP-bound Ras or phospho-MAPK and actin in whole cell lysates.  
(B) YAMC cells were transfected with vector or Myc-tagged dominant-negative 
Ras (S17N) and treated with TNF or EGF.  Whole cell lysates were subjected to 
Western blot analysis for phospho-MAPK and Ras.
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TNFR-induced cell survival is Raf-dependent.
Since Raf knockout mice are embryonic lethal (13), we generated conditional
Raf knockout mice by crossing mice harboring a Raf floxed allele (57) with those
constitutively expressing Cre recombinase under control of a villin promoter (137)
to specifically delete Raf from the intestinal epithelium. Cre expression in the
intestinal epithelium of constitutive villin-Cre mice was confirmed by
immunohistochemistry (Figure 4.6).  To characterize the extent of Cre
recombination, constitutive villin-Cre mice were crossed with Rosa26 reporter
mice.  As previously described in Chapter III, X-gal staining was performed to
assess LacZ expression in the colon and small intestinal epithelium.  Every crypt
was LacZ-positive demonstrating successful Cre recombination in the colon and
small intestine (Figure 4.7).  Rafflx/flx;vilCre  (Raf KOIE) mice develop normally and
unchallenged mice do not display a detectable intestinal phenotype.  Western
blot analysis was performed on epithelial and stromal fractions isolated from
wildtype and Raf KOIE mice colon to confirm loss of Raf expression (Figure 4.8).
Raf-1 was absent from the colon epithelium, but not the underlying stroma,
indicating that Raf ablation is specific to the epithelium.  Knockdown of Raf-1 had
no effect on expression of B-Raf, another Raf isoform expressed in the colon.
To determine if Raf is required for cell survival in the presence of TNF in vivo,
we treated wildtype and Raf KOIE mice with PBS or TNF for 24 h and performed
ISOL staining to detect apoptotic cells in the colon epithelium.  Following 24 h
TNF treatment, Raf KOIE mice exhibited increased apoptosis compared to
wildtype (Figure 4.9)(P<0.01), which was comparable to levels of apoptosis
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Figure 4.6:  Cre expression is restricted to the intestinal epithelium.   
Immunohistochemistry for Cre was performed on colon sections from 
constitutive villin-Cre expressing mice.  Sections were incubated without primary
antibody as a negative control.
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Figure 4.7:  Constitutive villin-Cre expression induces LacZ recombination.  
(A) Whole mount images of colon, distal small intestine (DSI), proximal small 
intestine (PSI) from Rosa26R; vilCre mouse stained with X-gal.  (d, distal; 
p, proximal) (B) Representative images of X-gal-stained  colon and small 
intestine.
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Figure 4.8:  Raf expression is absent in constitutive conditional Raf 
knockout mice.  Epithelial and stromal fractions were isolated from colons of 
wildtype and Raf KOIE mice and subjected to Western blot analysis for Raf, 
B-Raf and actin.  
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Figure 4.9:  Raf protects against TNF-stimulated colon epithelial cell 
apoptosis.  (A) ISOL was performed on colon sections from wildtype and Raf 
KOIE mice treated with PBS or TNF.  Scale bar = 125µM  (B) The graph 
represents the number of ISOL-positive cells per 100 colonic crypts.  Bars 
represent the mean value.
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detected in TNF-treated TNFR1 KO mice (Figure 4.1).  Similar findings were
obtained by immunostaining for active caspase-3 (data not shown).
In addition to in vivo studies, an organ culture model was used to assess the
role of Raf in TNF-induced cell survival.  Colon explants from wildtype and Raf
KOIE mice were treated with TNF (50 ng/ml) for 24 h and apoptosis was detected
by ISOL staining.  Cell death increased over four-fold in Raf KOIE explants
compared to explants from wildtype mice (Figure 4.10), further demonstrating a
requirement for Raf in cell survival following TNF exposure.
While Raf protects colon epithelial cells from TNF-induced apoptosis in vivo,
we wanted to develop a Raf-null epithelial cell line to characterize downstream
signaling events which are altered in the absence of Raf expression.  To this end,
colon and gastric epithelial cells were isolated from a Rafflx; Immortomouse
(Figure 4.11A).  A Rafflx cell line was established in culture and immunostaining
was performed for E-cadherin, cytokeratin, and smooth muscle actin. While Rafflx
cells stained positive for E-cadherin and cytokeratin, these cells did not express
the fibroblast marker, smooth muscle actin, demonstrating that the isolated cells
were derived from the epithelium (Figure 4.11B).  Unfortunately, expression of
lentiviral and retroviral Cre in these cells failed to induce recombination of the
Rafflx allele.
As an alternative approach to knock down Raf expression, RNA interference
was used in vitro to confirm the role of Raf in colon epithelial cell survival in
response to TNF.  Non-targeting or Raf siRNA duplexes were transfected into
YAMC cells, and Western blot analysis indicated that Raf siRNA was specific to
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Figure 4.10:  Raf promotes cell survival in response to TNF treatment in 
an organ culture model.  Colon explants from wildtype and Raf KOIE mice 
were treated with TNF (50 ng/ml) for 24 h.  (A)  H&E staining and (B) ISOL 
staining of colon explants.  The number of ISOL-positive cells/100 crypts is 
represented graphically. 
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Figure 4.11:  Isolation and characterization of Raf flx colon and gastric 
epithelial cells.  (A)  Phase contrast image of Raf flx colon and gastric epithelial 
cells isolated from Raf flx;Immortomice.  (B)  Epithelial cell lineage of Raf flx colon 
cells was confirmed by immunostaining for E-cadherin, cytokeratin, and smooth 
muscle actin.  
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Raf-1 and had no effect on B-Raf expression (Figure 4.12A).  Following 6 h TNF
treatment, siRNA-transfected YAMC cells were incubated with a cell-permeable,
fluorescent-tagged caspase inhibitor (SR-VAD-FMK) to detect cells actively
undergoing apoptosis (Figure 4.12B&C).  TNF-induced apoptosis was
significantly increased in the absence of Raf, similar to our findings in the in vivo
model (P<0.01).  These data were confirmed by TUNEL assay (data not shown).
Thus, Raf protects against TNF-induced apoptosis in colon epithelial cells both in
vivo and in vitro.
To determine if Raf kinase activity is required for cell survival in response to
TNF, TUNEL assays were performed on YAMC cells pretreated with DMSO or a
Raf-1 kinase inhibitor (GW5074) for 30 min, followed by TNF for 6 h.  While TNF
or the Raf kinase inhibitor alone did not have an effect on colon epithelial cell
survival, inhibition of Raf kinase activity promoted TNF-induced apoptosis in a
dose-dependent manner (Figure 4.13).  Treatment with TNF and wortmannin, a
PI-3 kinase inhibitor, was used as a positive control for the assay.  These data
indicate that Raf kinase activity is required for cell survival in response to TNF in
vitro.
MEK activation is not required for cell survival downstream of TNFR1.
As shown in Figure 4.3, TNF stimulates MAPK activation in mouse colon
epithelial cells through TNFR1.  While MEK, the kinase directly upstream of
MAPK in the canonical signaling cascade, is the best characterized downstream
target of Raf activation, novel substrates for Raf are being investigated (60).  To
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Figure 4.12:  Raf is required for colon epithelial cell survival in response to
TNF.  (A)  Western blot analysis was performed on whole cell lysates of non-
targeting and Raf siRNA-transfected cells for Raf, B-Raf, and actin.  (B) Multi-
caspase activation assay was performed on non-targeting and Raf siRNA-
transfected YAMC cells following TNF treatment for 6 h.   Caspase activation is 
shown in red, DAPI-stained nuclei in blue.  Scale bar = 20µM   (C) The number 
of caspase-positive cells is represented.  Bars represent the mean value. 
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Figure 4.13:  Raf kinase inhibitor induces apoptosis in colon epithelial cells 
following TNF exposure. YAMC cells were pre-treated with Raf kinase inhibitor 
(5-20 µM) or wortmannin (100 nM) followed by 6 h TNF treatment (100 ng/ml).  
(A)  Apoptosis was detected by TUNEL assay and (B) percent TUNEL-positive 
cells were represented graphically.
0
2
4
6
8
10
12
DM
SO TN
F
Ra
fIn
h 2
0u
M
Ra
fIn
h 5
uM
+ 
TN
F
Ra
fIn
h 1
0u
M
+ 
TN
F
Ra
fIn
h 2
0u
M
+ 
TN
F
wo
rtm
an
nin
+
TN
F
p
er
ce
nt
 T
U
N
EL
-p
os
it
iv
e 
ce
lls
B
DMSO TNFuntreated
wortmannin +
TNF
Raf inh 20 µM Raf inh 5 µM Raf inh 10 µM Raf inh 20 µM
TNF 6 h
TU
N
EL
A
14
97
98
address whether TNF-mediated anti-apoptotic signaling requires MAPK
signaling, YAMC cells were pre-treated with two MEK inhibitors, PD98059
(20mM) or U0126 (10mM), followed by 6 h TNF treatment.  Western blot analysis
showed that both inhibitors effectively blocked MAPK phosphorylation after 10
min TNF stimulation (Figure 4.14A). However, IkB degradation was independent
of MAPK activation, demonstrating that MAPK activation is not required to
promote NF-kB signaling in response to TNF in mouse colon epithelial cells.
Consistent with this result, TNF did not stimulate apoptosis as detected by
TUNEL in the presence of either MEK inhibitor compared to a phosphoinositide 3
(PI3)-kinase inhibitor, wortmannin (Figure 4.14B)(141).  Taken together, these
data indicate that Raf promotes cell survival in the presence of TNF through a
MEK-independent mechanism.
Raf mediates cell survival through activation of NF-kB.
Since inhibition of MEK kinase activity had no effect on TNF-mediated cell
survival or TNF-induced IkB degradation, we hypothesized that Raf might
promote cell survival through activation of NF-kB.  To address this hypothesis,
YAMC cells were transfected with siRNA against Raf, NF-kB p65, IkB, or both
Raf and IkB.  Western blot analysis for Raf, IkB, NF-kB p65, or actin was
performed on whole cell lysates to confirm the respective inhibition of protein
expression by siRNA (Figure 4.15A).  In non-targeting siRNA-transfected cells,
TNF promotes nuclear translocation of NF-kB after 30 min; however, knockdown
of IkB expression resulted in constitutive NF-kB p65 nuclear translocation as
Figure 4.14:  Anti-apoptotic signaling downstream of TNF receptors is 
MEK-independent.  (A) YAMC cells were pre-treated with DMSO, PD98059, or 
U0126 for 30 min followed by TNF for 10 min or EGF for 5 min.  Western blot 
analysis was performed to detect phospho-MAPK, IκB, and actin.  (B) TUNEL 
assay was performed in YAMC cells pre-treated with DMSO, PD98059, U0126, 
or wortmannin for 30 min and then treated with TNF for 6 h.  Percent TUNEL-
positive cells shown. Bars represent the mean value.  
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Figure 4.15: Loss of IκB expression results in constitutive NF-κB nuclear 
translocation.  YAMC cells were transfected with non-targeting, NF-κB p65, 
Raf and/or IκBα siRNA.  (A)  Western blot analysis was performed for NF-κB 
p65, Raf, IκB, and actin. (B) Immunofluorescence for NF-κB p65 subunit (red) 
was performed on siRNA-transfected cells treated with TNF for 30 min.  
Nuclei were stained with DAPI (blue).  Scale bars = 20µm 
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shown by immunocytochemistry (Figure 4.15B).  siRNA-transfected cells were
treated with TNF for 6 h and apoptosis detected by multi-caspase activation
assay (Figure 4.16).  TNF stimulated apoptosis in the absence of Raf or NF-kB
p65; however, constitutive activation of NF-kB through inhibition of IkB
expression protected colon epithelial cells from TNF-induced apoptosis in the
absence of Raf expression (P<0.01).
To determine whether Raf expression is required for TNF-induced NF-kB
activation in vivo, wildtype, TNFR1 KO, and Raf KOIE mice were injected with
PBS or TNF for 1 or 2 h, and immunohistochemistry performed to detect
phosphorylated NF-kB p65 (S276) on colon sections (Figure 4.17).  TNF
treatment at both time points stimulated increased NF-kB p65 phosphorylation in
wildtype, but not TNFR1 KO or Raf KOIE mice (P<0.001, P=0.02, P=0.03).
Furthermore, Raf was required for increased expression of an anti-apoptotic NF-
kB target gene, cIAP1, in the colon epithelium following 24 h TNF exposure
(Figure 4.18) (P=0.03).  cIAP1 inhibits apoptosis by preventing activation of both
pro-form and mature caspases (81).  These data indicate that Raf is required for
activation of anti-apoptotic NF-kB target genes to promote cell survival
downstream of TNFR1.
Discussion
In this study, we demonstrate that TNFR1 is required for ERK and NF-kB
activation and colon epithelial cell survival in response to TNF stimulation both in
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Figure 4.16: NF-κB activation rescues TNF-induced apoptosis in the 
absence of Raf.  YAMC cells were transfected with non-targeting, NF-κB p65, 
Raf and/or IκBα siRNA.  Percent of caspase-positive cells following treatment 
with TNF for 6 h.  Bars represent the mean value. 
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Figure 4.17:  Raf is required for TNF-stimulated NF-κB activation in vivo.
(A)  Immunostaining for NF-κB p65 phospho-Ser276 was performed on colon 
sections of wildtype, Raf KOIE, and TNFR1 KO (R1KO) mice injected with TNF 
for 1 or 2 h.  Scale bar = 125µM (B) Number of NF-κB p65 phospho-Ser276-
positive cells per 100 crypts.   Bars represent the mean value.
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Figure 4.18: Raf is required for increased expression of cIAP1 in response 
to TNF stimulation.  (A) Immunostaining for cIAP1 (red) was performed on 
colon sections of wildtype and Raf KOIE mice injected with TNF for 24 h.  DAPI-
stained nuclei are blue.  Scale bar = 20µM  (B)  Number of cIAP1-positive cells 
per 100 crypts are represented graphically.  Bars represent the mean value.  
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vitro and in vivo.   We have previously shown that KSR promotes anti-apoptotic
signaling, and now demonstrate that Raf-1, a KSR substrate, is also required for
cell survival in response to TNF.  Inhibition of the Raf substrate MEK did not
induce apoptosis in TNF-treated colon epithelial cells; however, loss of NF-kB
signaling resulted in increased cell death.   Furthermore, the absence of Raf
expression inhibits TNF-induced NF-kB p65 phosphorylation and expression of
an NF-kB anti-apoptotic target gene, cIAP1.  Taken together, these data
demonstrate Raf promotes colon epithelial cell survival through NF-kB
downstream of TNFR1 activation.
In contrast to EGF, TNF stimulates Raf activation in a Ras-independent
manner (Figure 4.4).  Interestingly, previous reports have shown that Ras is not
required for Raf-mediated MAPK signaling involved in calcium-induced
differentiation pathways in keratinocytes (195).  In addition, lipopolysaccharide
(LPS)-stimulated macrophage differentiation occurs through Ras-independent,
protein kinase C (PKC) or phosphatidylcholine-specific phospholipase C
activation (196).  KSR directly interacts with Raf at the plasma membrane
(136,197), and thus we propose in the absence of Ras activation, KSR promotes
recruitment of Raf to the membrane.  Following membrane translocation, TNF-
induced KSR kinase activity is required for Raf threonine phosphorylation and
subsequent MAPK activation in colon epithelial cells (61).
Although inhibition of KSR kinase activity toward Raf results in decreased
MAPK activation (61), we now show that the TNF-mediated cell survival
response does not require MEK signaling (Figure 4.14).  Similar findings were
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reported for anti-apoptotic signaling in the cardiac-specific Raf knockout mouse,
where deletion of Raf resulted in increased ASK1 activity in a MEK-independent
manner (56).  However, Raf knockdown in YAMC cells by siRNA shows no
change in the phosphorylation of ASK1 or other pro-apoptotic kinases such as
JNK or p38 (data not shown).
The Raf mutant (T481A) activates a NF-kB reporter plasmid independent of
MEK (50), consistent with our findings that MEK inhibition does not block TNF-
induced NF-kB activation (Figure 4.14).  Taken together, these data suggest that
Raf mediates NF-kB activation through a novel MEK-independent mechanism.
We have shown that the absence of KSR impairs TNF-stimulated NF-kB
nuclear translocation both in vitro and in vivo (61,62,136).  Surprisingly, NF-kB
p65 nuclear translocation following TNF treatment of colon epithelial cells does
not require Raf (Figure 4.15); however, Raf expression is necessary for TNF-
stimulated NF-kB p65 serine 276 phosphorylation in vivo (Figure 4.17).  Thus,
KSR activates NF-kB upstream of Raf-mediated NF-kB p65 phosphorylation,
demonstrating that both KSR and Raf are necessary for TNF-induced NF-kB
signaling.
NF-kB p65 subunit phosphorylation on S276 in the Rel homology domain
(RHD) enhances DNA binding as well as the interaction between p65 and
CBP/p300 (198,199).  Overexpression of a p65 S276A mutant in p65 KO mouse
embryonic fibroblasts (MEFs) shows that TNF-induced IL-6 expression and cell
survival require phosphorylation at this site (200).  Further analysis of the
requirement for S276 phosphorylation in NF-kB transcriptional activation
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indicated that the phosphorylation state of p65 may target NF-kB to distinct cis-
acting elements to activate gene expression in a cell context-dependent manner
(201).  Raf promotes NF-kB p65 S276 phosphorylation in dendritic cells following
activation of a c-type lectin, DC-SIGN (202), indicating that Raf may activate NF-
kB in additional cell types.  Our data demonstrate a novel regulatory mechanism
through which Raf promotes TNF-stimulated NF-kB p65 S276 phosphorylation
independent of MEK activation.
Based on our current results and previous reported findings, we propose a
model (Figure 4.19) in which binding of TNF to TNFR1 promotes recruitment of
FAN [factor-associated with neutral sphingomyelinase (N-SMase) activation]
(203) to the N-SMase domain (NSD) of TNFR1 (204).  N-SMase hydrolyzes
sphingomyelin in the plasma membrane to increase intracellular ceramide
production (203,205).  Ceramide can then bind to and activate KSR, which
phosphorylates Raf on threonine residues in response to TNF and EGF
treatment (32,61,190,206-208).  Through an unknown mechanism, Raf enhances
NF-kB S276 phosphorylation in a MEK-independent manner to protect against
colon epithelial cell apoptosis.
In regard to the colon epithelium, TNF has been implicated in promoting cell
survival through NF-kB in response to inflammation in vivo.  Mice with a deletion
of the IKKg/NEMO subunit in the intestinal epithelium are more susceptible to
TNF-induced apoptosis.  These findings support our model by demonstrating that
the loss of an anti-apoptotic signaling molecule downstream of TNFR1, such as
NF-kB, Raf or KSR, disrupts intestinal homeostasis by downregulating anti-
Figure 4.19: TNFR1 regulation of both pro- and anti-apoptotic signaling in 
colon epithelial cells. Binding of TNF to TNFR1 induces production of neutral 
sphingomyelinase (N-SMase) to generate intracellular ceramide, which can bind 
to and activate KSR. Raf, a KSR substrate,promotes NF-κB phosphorylation 
through a MEK-independent mechanism, whereas KSR stimulates NF-κB 
through IKKα activation. Both Raf and KSR are required to induce anti-apoptotic
signaling to balance pro-apoptotic pathways activated downstream of the TNFR1 
death domain.
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apoptotic signaling and shifts cells toward an apoptotic program (161). NEMO
KOIE mice develop spontaneous colitis due to decreased barrier integrity,
whereas crossing these mice into a TNFR1 KO background rescues the colitis
phenotype.  Although the NEMO KOIE/TNFR1 KO mice show no sign of
inflammation, it is unclear whether TNFR1 signaling in the colon epithelium or
immune cells contributes to the development of colitis.
A recent study showed that blocking TNF reduced initiation and progression
of inflammation-associated tumorigenesis (209), which is consistent with data
demonstrating that IKKB inhibition results in decreased tumor multiplicity
following azoxymethane (AOM)/DSS exposure (126). Raf kinase inhibitors are
currently used in the treatment of hepatocellular and renal cell carcinoma (168),
suggesting that further investigation into the role of TNF activation of Raf
signaling may lead to the identification of novel mediators of colitis-associated
cancer.
In summary, these findings show that Raf functions as a molecular cell
survival switch to enhance anti-apoptotic signaling in response to TNF activation
of TNFR1 by promoting NF-kB.  Our model suggests that TNF stimulates Raf
activity through a novel Ras-independent mechanism, likely involving KSR based
on our prior results.  Furthermore, Raf promotes NF-kB phosphorylation
independent of MAPK signaling to support cell survival.  In the absence of Raf,
TNF stimulation of TNFR1 results in increased apoptosis, which may lead to
disruption of epithelial barrier function and mucosal inflammation.  These data
demonstrate an important role for Raf in the maintenance of intestinal
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homeostasis.  Further understanding the role of Raf in cytokine signaling in the
colon epithelium under non-inflammatory conditions may lead to the development
of novel therapeutics for the treatment of IBD.
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CHAPTER V
SUMMARY AND FUTURE DIRECTIONS
Summary of findings
Previous studies in our lab demonstrated that an upstream activator of Raf
kinase, KSR, is required for cell survival in response to TNF stimulation (136).
Additionally, KSR-mediated Raf threonine phosphorylation is increased during
active colitis in the IL-10 KO mouse model, suggesting that Raf activation may
regulate cellular responses to inflammation.  The studies presented here begin to
define the mechanism by which Raf regulates colon epithelial cell survival.  In
response to epithelial injury and pro-inflammatory cytokine production, Raf
activates NF-kB through a novel MEK-independent mechanism.
The data demonstrate that Raf protects against inflammation and crypt injury
during acute colitis.  Loss of Raf promotes colon epithelial cell apoptosis
following injury, and inhibits the proliferative response necessary to regenerate
the epithelial barrier during recovery.  Furthermore, Raf enhances epithelial
proliferation through activation of MAPK, whereas Raf promotes cell survival
through a MEK-independent mechanism.  Activation of Raf or NF-kB is required
to protect against DSS-induced apoptosis in YAMC cells.  However, constitutive
NF-kB activation rescued cells from DSS-induced cell death in vitro in the
absence of Raf, positioning NF-kB downstream of Raf activation.  Furthermore,
Raf expression was required for NF-kB p65 nuclear translocation in the colon
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epithelium during DSS-induced injury in vivo.  Taken together, these data
demonstrate that Raf stimulates NF-kB to protect against colon epithelial cell
apoptosis in DSS colitis (Figure 5.1).
Previous reports characterizing cytokine expression during DSS colitis
showed that increased TNF and IL-6 production contribute to epithelial injury
(129).  Experiments conducted in the present study to address the role of Raf in
TNFR signaling indicate that Raf is a key regulator of cell survival both in vitro
and in vivo.  Although Raf is not required for TNF-stimulated NF-kB nuclear
translocation, short term TNF treatment of Raf KOIE mice demonstrated that Raf
promotes NF-kB p65 phosphorylation (Figure 4.17).  In addition, TNF-induced
expression of an NF-kB anti-apoptotic target gene, cIAP1, was blocked in the
absence of Raf.  Further analysis showed that Raf promotes NF-kB
phosphorylation downstream of TNFR1 activation (Figure 5.1).  Interestingly,
pharmacological inhibition of MEK kinase activity did not induce apoptosis in
YAMC cells following exposure to TNF.  These data indicate that Raf protects
against TNF-induced apoptosis through NF-kB activation in a MEK-independent
manner.
This is the first report characterizing the role of Raf in the colon epithelium.
Although Raf is not required for maintenance of the intestinal epithelium in
unchallenged mice, these findings demonstrate that it is essential for promoting
colon epithelial cell survival during inflammation.  Furthermore, the identification
Figure 5.1:  Raf promotes colon epithelial cell survival through NF-κB 
in a MEK-independent manner.  Raf stimulates IκB degradation resulting in 
NF-κB nuclear translocation following DSS exposure.  While Raf activates 
ERK to promote epithelial hyperproliferation during recovery from DSS colitis, 
MEK activation is also pro-apoptotic in response to DSS exposure.  TNF 
stimulation of TNFR1 results in increased intracellular ceramide generation 
which activates kinase suppressor of Ras (KSR), and its substrate, Raf.  
Following TNF exposure, KSR induces NF-κB nuclear translocation, whereas 
Raf promotes NF-κB p65 phosphorylation.  Raf activation of NF-κB occurs
through a novel MEK-independent mechanism.    
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of additional MEK-independent Raf signaling pathways involved in cell survival
complements and expands the known functions of Raf in the literature.
Raf in DSS-induced cytokine signaling
Our data indicate that Raf is an essential regulator of colon epithelial cell
survival in response to pro-inflammatory stimuli.  While several studies have
highlighted the importance of TNF production in the pathogenesis of colitis, it
remains unclear as to which cytokines promote Raf activation in response to
DSS colitis.  Elevated TNF levels play an important role in DSS-induced epithelial
injury (129,130); however, TNF KO mice develop more severe colitis in response
to DSS compared to wildtype controls (177).  These findings emphasize the
importance of cytokines other than TNF in promoting inflammation and crypt
damage associated with DSS colitis.
One example of another cytokine that may promote Raf activation is IL-1.  IL-
1 is elevated in lamina propria macrophages following DSS treatment (210) and
in inflamed mucosa of IBD patients (211).  Similar to our proposed model of
TNFR-induced Raf activation, Huwiler et al. demonstrated that IL-1 stimulates
Raf through generation of endogenous ceramide in fibroblasts (28), indicating IL-
1 may promote KSR activation of Raf through increased ceramide production.
IL-1 is also a potent activator of NF-kB signaling; therefore, investigating the role
of Raf in IL-1-induced NF-kB activation may extend our current findings to
additional cytokine signaling pathways.
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TNF and TNFR signaling in the colon epithelium
TNF activation of TNFR can promote cell survival or apoptosis in a cell
context-dependent manner; however, the role of TNFR in colitis is not clearly
defined.  Studies performed to evaluate the role of TNFR1 in acute colitis showed
that immune progenitor reconstitution by transplanting wildtype bone marrow in
TNFR1 KO mice results in protection against severe DSS colitis (212).  While
these data demonstrate that TNFR1 expression in bone marrow-derived cells
contributes to maintenance of intestinal homeostasis, it is important to consider
that these experiments were performed in the absence of adaptive immunity.
Whereas TNFR1 promotes cell survival in the colon epithelium, loss of TNFR1
inhibited macrophage apoptosis indicating that TNF signaling through TNFR1 is
pro-apoptotic in this cell type.  Unfortunately, it is difficult to determine the exact
contribution of TNF signaling in inflammation because of paracrine signaling
between myeloid and epithelial cells.  The generation of conditional TNFR KO
mice is necessary to definitively address the cell-specific role of TNFRs in
inflammation-induced injury.  DSS treatment of conditional intestinal epithelium-
specific TNFR KO mice would allow us to examine the role of each TNFR in
colon epithelium in response to injury and inflammation.  In addition, generation
of these mice would enable further investigation of the requirement for TNFR1 in
colon epithelial cell survival.
As discussed in Chapter IV, TNF binding to TNFR1 promotes both pro-
and anti-apoptotic signaling pathways in the colon epithelium.  We hypothesize
that activation of TNFR1 signaling may occur in a dose-dependent manner
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following TNF stimulation.  Therefore, the amount of soluble TNF available in the
system may alter cellular responses downstream of TNFR1.  Previous studies
demonstrated that TNF-induced signaling pathways through TNFR1 can be
coordinated in a temporal manner (213).  In B-cells, TNF stimulates N-SMase
activation through TNFR1 NSD prior to the generation of acid SMase (A-SMase)
through activation of the TNFR1 death domain (213). Induction of N-SMase may
contribute to cell survival (214-216), while generation of A-SMase results in
apoptosis (214,217,218).  Thus, we hypothesize that activation of neutral SMase
to promote KSR- and Raf-mediated cell survival signaling may counterbalance
acid SMase-induced apoptotic signaling in the colon epithelium; however, the
role of ceramide in Raf activation has not yet been addressed.  The period
between activation of neutral and acid SMases may allow the cell to activate a
negative-feedback loop to inhibit further TNFR signaling.  One example of
feedback inhibition is the proteolytic cleavage of TNFR at the plasma membrane
by metalloproteinases, which results in the shedding of soluble TNFR to prevent
further activation of downstream signaling pathways (219).  Therefore, TNF-
induced anti-apoptotic signaling through NF-kB may function as a first response
to permit epithelial cells (220) or innate immune cells (221) to shed decoy
receptors as a negative feedback mechanism to inhibit TNF-induced colon
epithelial cell apoptosis.
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Raf involvement in NF-kB signaling
As demonstrated in Chapters III and IV, Raf can promote activation of NF-kB
at multiple steps of the NF-kB signaling pathway.  In response to DSS, Raf is
required for NF-kB nuclear translocation, whereas TNF stimulates Raf-
dependent NF-kB phosphorylation, but NF-kB nuclear translocation is Raf-
independent.  One possible explanation for this difference may be that DSS
stimulates Raf through cytokine receptors other than TNFR to promote Raf-
dependent NF-kB activation, as discussed earlier in this section.  Regardless of
the stimulus, the mechanism by which Raf induces NF-kB nuclear translocation
or phosphorylation remains unknown.  While overexpression studies using
constitutively activated Raf showed increased NF-kB activation in a transformed
cell line (222), this is the first demonstration of endogenous Raf mediating NF-kB
activation in cell culture and in vivo.  Although Raf is a MAPKKK, similar to MEKK
or NIK, there is no evidence that Raf directly phosphorylates the IKKs (163). One
report shows that Raf and IkBa may physically interact in a yeast two-hybrid
screen (222); however, Raf expression was not required for IkB phosphorylation
in our studies.  Rather, Raf may indirectly promote NF-kB translocation to the
nucleus through the activation of NF-kB binding partners or other kinases
involved in NF-kB signaling.
Similarly, it is unknown whether Raf can directly phosphorylate NF-kB p65 at
serine 276.  Although protein kinase A (PKA) can phosphorylate this site (198), it
has been demonstrated that mitogen and stress-activated kinase-1 (MSK1)
phosphorylates S276 in the nucleus following TNF stimulation (223).  Vanden
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Berghe et al. showed that the upstream activators of MSK1, p38 and ERK
MAPK, were required for NF-kB activation in TNF-treated fibroblasts (224);
however, our results demonstrate that ERK MAPK is not required for TNF-
induced NF-kB activation.  Therefore, further investigation is necessary to
determine the exact mechanism by which Raf stimulates NF-kB p65
phosphorylation in the colon epithelium following TNF exposure.
Recently, Raf was shown to promote NF-kB p65 S276 phosphorylation and
subsequent acetylation through an unknown mechanism in dendritic cells
following activation of a c-type lectin, DC-SIGN, which functions to mediate
dendritic cell survival (202).  Interestingly, lipopolysaccharide (LPS)-induced
stimulation of Toll-like receptor (TLR)-4 was required for NF-kB nuclear
translocation following which Raf-dependent NF-kB p65 phosphorylation induced
transcription of NF-kB target genes.  These data suggest multiple signals from
cell surface receptors cooperate to stimulate NF-kB activation.  A similar series
of receptor-driven events may be required for NF-kB activation in the colon
epithelium in response to DSS treatment, in contrast, TNFR-initiated signaling
appears to be sufficient to promote both TNF-induced NF-kB nuclear
translocation and subsequent Raf-dependent p65 phosphorylation,.
Although NF-kB nuclear translocation and phosphorylation are critical for
transcriptional activation of NF-kB target genes, recent studies have revealed
AFigure 5.2:  Potential involvement of Raf in regulating NF-κB transcriptional 
co-activators.  (A)  Raf may mediate ERK phosphorylation of ribosomal protein 
subunit 3 (RPS3) resulting in RPS3 nuclear translocation where it associates with 
NF-κB/DNA complexes to enhance transcription of NF-κB target genes.  
(B) During cell cycle progression, Raf-induced Rb phosphorylation relieves 
repression of E2F1.  Raf may also regulate E2F1 availability and subsequent 
association with NF-κB at DNA promoter regions through a similar mechanism.
B
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additional components of the NF-kB/DNA complex (Figure 5.2)(225).  Among
these findings is a report showing that ribosomal protein S3 (RPS3) binds to the
NF-kB p65 Rel homology domain (RHD) and enhances the binding association
between p65 and DNA resulting in expression of NF-kB-dependent target genes.
In this model, ERK phosphorylation of RPS3 in the cytoplasm results in RPS3
nuclear translocation (226,227) where it can then associate with the NF-kB/DNA
complex.  While initial studies show that TNF stimulates RPS3 translocation to
the nucleus in T-cells (225), it would be of interest to test the requirement for Raf
in RPS3 nuclear translocation in the colon epithelium following various stimuli.
Following nuclear translocation, NF-kB also recruits E2F1 to promote
transcriptional activation of target genes (228).  Not only are NF-kB and E2F1
required for expression of several LPS-induced target genes, but both proteins
can occupy the same DNA promoter regions.  E2F1 is sequestered through
binding interactions with retinoblastoma (Rb) protein to inhibit activation of
transcription. During regulation of cell cycle progression, Raf can directly
phosphorylate and inactivate Rb, reversing Rb-mediated repression of E2F1
(229), suggesting that Raf may regulate E2F1 availability to promote NF-kB
transcriptional activation.
Raf in colon cancer development
These studies indicate an essential role for Raf in maintaining colon
epithelial integrity through regulation of both cell survival and proliferation in
response to acute colitis.  These biological processes also play a significant role
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in tumor development.  Tumorigenesis occurs following the unrestricted
proliferation of a cell with genetic mutations (230,231).  Defects in the initiation of
apoptotic signaling and progression past cell cycle checkpoints allow the mutated
cell to escape normal regulatory processes resulting in tumor formation.
IBD patients are at a higher risk to develop colon cancer due to repeated
cycles of inflammation and wound repair (169).  This link between chronic
inflammation and cancer in the colon was confirmed experimentally through the
development of an inflammation-associated cancer model in mice (126).  In this
model, mice receive a single dose of carcinogen (azoxymethane, AOM) followed
by multiple rounds of DSS administration to induce chronic inflammation.  This
protocol induces adenomas in treated mice with high penetrance and frequency.
Greten et al. showed that inhibition of NF-kB signaling by IKKb deletion in the
colon epithelium resulted in increased tumor formation following AOM/DSS
treatment (126).  Since loss of Raf expression in the colon epithelium results in
increased inflammation and impaired NF-kB signaling, increased tumorigenesis
in IKKb KOIE mice suggests that Raf may function as a tumor suppressor.  In
contrast, tumorigenesis may be inhibited due to increased cell death and
decreased proliferation in Raf KOIE mice following inflammation-induced injury.
Regardless of whether Raf promotes or suppresses tumorigenesis, elucidating
the role of Raf in inflammation-associated carcinogenesis would provide valuable
insight in determining the course of cancer therapy.  Sorafenib, a multikinase
inhibitor that also inhibits Raf kinase, is currently used in the treatment of renal
cell and hepatocellular carcinoma (232), with clinical trials in process for other
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types of cancer (233).  Thus, it would be beneficial to determine whether Raf
inhibition promotes tumor formation in inflammation-associated colon cancer.
Concluding remarks
Raf kinase and its role in MAPK activation have been extensively studied
for the last twenty years; however, much about Raf function remains unknown.
Only recently have we begun to characterize and identify the role of Raf in
specific cell types and the diversity of cellular stimuli that leads to Raf activation
outside of receptor tyrosine kinase signaling.  The involvement of Raf in several
disease states, including cancer, illustrates the need for further investigation into
the mechanism by which Raf regulates cellular processes, including cell survival.
We demonstrate that Raf promotes anti-apoptotic signaling through a MEK-
independent mechanism, indicating a role for novel Raf substrates in colon
epithelial cell survival.  The studies described here begin to demonstrate the
importance of Raf signaling in maintenance of the colon epithelium and link Raf
to a known mediator of inflammatory signaling, NF-kB.
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